U.S. patent application number 15/093335 was filed with the patent office on 2016-09-01 for peptidomimetic macrocycles.
The applicant listed for this patent is AILERON THERAPEUTICS, INC.. Invention is credited to David Allen Annis, Huw M. Nash.
Application Number | 20160251399 15/093335 |
Document ID | / |
Family ID | 42340294 |
Filed Date | 2016-09-01 |
United States Patent
Application |
20160251399 |
Kind Code |
A1 |
Nash; Huw M. ; et
al. |
September 1, 2016 |
PEPTIDOMIMETIC MACROCYCLES
Abstract
The present invention provides novel peptidomimetic macrocycles
and methods of using such macrocycles for the treatment of viral
disease.
Inventors: |
Nash; Huw M.; (Concord,
MA) ; Annis; David Allen; (Cambridge, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AILERON THERAPEUTICS, INC. |
Cambridge |
MA |
US |
|
|
Family ID: |
42340294 |
Appl. No.: |
15/093335 |
Filed: |
April 7, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14853894 |
Sep 14, 2015 |
|
|
|
15093335 |
|
|
|
|
13129118 |
Nov 1, 2011 |
9175047 |
|
|
PCT/US2010/021091 |
Jan 14, 2010 |
|
|
|
14853894 |
|
|
|
|
61144706 |
Jan 14, 2009 |
|
|
|
Current U.S.
Class: |
530/321 |
Current CPC
Class: |
A61K 38/10 20130101;
C07K 7/54 20130101; C07K 7/56 20130101; C07K 7/64 20130101; C07K
14/005 20130101; A61P 43/00 20180101; C07K 7/06 20130101; C07K 7/08
20130101; C12N 2760/16022 20130101; A61K 38/00 20130101; A61P 31/16
20180101 |
International
Class: |
C07K 7/54 20060101
C07K007/54; C07K 7/64 20060101 C07K007/64 |
Claims
1-23. (canceled)
24. A peptidomimetic macrocycle of the formula: ##STR00109##
wherein: each A, C, D, and E is independently a natural or
non-natural amino acid; each B is independently a natural or
non-natural amino acid, amino acid analog, or ##STR00110## each
R.sub.1 and R.sub.2 are independently --H, alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo-; each
R.sub.3 is independently hydrogen, alkyl, alkenyl, alkynyl,
arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally
substituted with R.sub.5; each L is independently a
macrocycle-forming linker of the formula -L.sub.1-L.sub.2-; each
L.sub.1 and L.sub.2 is independently alkylene, alkenylene,
alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene,
cycloarylene, heterocycloarylene, or [--R.sub.4--K--R.sub.4].sub.n,
each being optionally substituted with R.sub.5; each R.sub.4 is
independently alkylene, alkenylene, alkynylene, heteroalkylene,
cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each
K is independently O, S, SO, SO.sub.2, CO, CO.sub.2, or CONR.sub.3;
each R.sub.5 is independently halogen, alkyl, --OR.sub.6,
--N(R.sub.6).sub.2, --SR.sub.6, --SOR.sub.6,
--SO.sub.2R.sub.6,--CO.sub.2R.sub.6, a fluorescent moiety, a
radioisotope or a therapeutic agent; each R.sub.6 is independently
--H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl,
heterocycloalkyl, a fluorescent moiety, a radioisotope or a
therapeutic agent; each R.sub.7 is independently --H, alkyl,
alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl,
cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl,
optionally substituted with R.sub.5, or part of a cyclic structure
with a D residue; each R.sub.8 is independently --H, alkyl,
alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl,
cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl,
optionally substituted with R.sub.5, or part of a cyclic structure
with an E residue; amino acids represented as $ are alpha-Me
S5-pentenyl-alanine olefin amino acids; each v and w are
independently integers from 1-1000; u is an integer from 1-10; each
x, y and z is independently integers from 0-10; and each n is
independently an integer from 1-5, wherein the peptidomimetic
macrocycle further comprises a triazole-containing crosslinker.
25. The peptidomimetic macrocycle of claim 24, wherein the
peptidomimetic macrocycle comprises a helix.
26. The peptidomimetic macrocycle of claim 25, wherein the helix
includes 1 to 5 turns.
27. The peptidomimetic macrocycle of claim 25, wherein the length
of the macrocycle-forming linker L is approximately 5 .ANG. to 9
.ANG. per turn of the helix.
28. The peptidomimetic macrocycle of claim 25, wherein the length
of the macrocycle-forming linker L is approximately 8 .ANG. to 6
.ANG. per turn of the helix.
29. The peptidomimetic macrocycle of claim 24, wherein the
peptidomimetic macrocycle comprises an
.alpha.,.alpha.-disubstituted amino acid.
30. The peptidomimetic macrocycle of claim 24, wherein x+y+z=2, 3,
or 6.
31. The peptidomimetic macrocycle of claim 24, wherein the
peptidomimetic macrocycle comprises an alpha helix.
32. The peptidomimetic macrocycle of claim 24, wherein R.sub.1 is
alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with
halo-.
33. The peptidomimetic macrocycle of claim 24, wherein R.sub.1 and
R.sub.2 are independently alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl,
unsubstituted or substituted with halo-.
34. The peptidomimetic macrocycle of claim 24, wherein R.sub.1 and
R.sub.2 are independently alkyl.
35. The peptidomimetic macrocycle of claim 24, wherein R.sub.1 and
R.sub.2 are methyl.
36. The peptidomimetic macrocycle of claim 24, wherein the
triazole-containing crosslinker stabilizes a secondary structure of
the peptidomimetic macrocycle.
Description
CROSS REFERENCE
[0001] This application claims the benefit of U.S. Provisional
Application No. 61/144,706, filed Jan. 14, 2009, which is
incorporated herein in its entirety by reference.
BACKGROUND OF THE INVENTION
[0002] Seasonal influenza infection is a major health concern for
first-world and developing nations alike. Each year in the United
States, five- to twenty-percent of the population gets the flu,
more than 200,000 people are hospitalized from flu complications,
and about 36,000 people die from flu. Worldwide, influenza causes
tens of millions of respiratory illnesses and 250,000 to 500,000
deaths each year. New strains of avian influenza that are
transmissible to humans are a critical concern for global health
because these flu strains could yield pandemic disease for which no
immunity exists, potentially resulting in millions of fatalities.
"Avian flu" refers to a pathogenic avian influenza subtype that is
highly contagious among birds and causes high mortality among
domestic poultry. Outbreaks of avian flu among poultry and wild
birds are ongoing in a number of countries, and at least three
subgroups of avian flu viruses have infected humans to date. While
avian flu infections of humans are rare, and most cases have been
associated with direct poultry contact during outbreaks among
livestock, infection in humans is very serious when it does occur:
to date, over half of all reported human cases have been fatal.
Since first reported in Hong Kong in 1996, the World Health
Organization has carefully tracked avian flu and instances of
animal-to-human influenza transmission, with confirmed cases
reported from China, Indonesia, and Southeast Asia; Pakistan; Iraq;
Egypt; and elsewhere, with 385 cases resulting in 243 deaths
worldwide. While there is no evidence of sustained human-to-human
transmission, instances of human-to-human spread of avian flu may
have occurred. Since all influenza viruses have the ability to
rapidly mutate, there is considerable concern that avian flu may be
able to infect humans more easily and become communicable from one
person to another. Also, avian flu virus strains have not infected
many humans worldwide, so there is little or no immune protection
against these strains in the human population; therefore, an
influenza pandemic could easily occur if sustained avian flu virus
transmission were to develop.
[0003] Three classes of influenza viruses, A, B and C, are
responsible for human flu, with influenza A and B viruses causing
seasonal epidemics of disease almost every winter. Influenza A
viruses are divided into subtypes based on characteristics of two
proteins, hemagglutinin (H) and neuraminidase (N), on the surface
of the virus. There are 16 different hemagglutinin subtypes and 9
different neuraminidase subtypes, with H1N1 and H3N2 being the most
common subtypes found in humans. The avian flu virus refers to
influenza A H5N1. Influenza A is a negative-sense (3' to 5')
single-stranded RNA virus. Its viral genome, which encodes 11
proteins (HA, NA, NP, M1, M2, NS1, NEP, PA, PB1, PB1-F2, PB2) in
its RNA, cannot be translated into protein directly; rather, the
virus depends on its RNA-dependent RNA polymerase to transcribe its
genome to positive-sense RNA prior to translation. RNA-dependent
RNA polymerases have no mammalian counterpart, which renders
species selectivity less problematic in the development of
therapeutics that target this enzyme. Other examples of viral
RNA-dependent RNA polymerases include polioviral 3Dpol, vesicular
stomatitis virus L, and hepatitis C virus NS5b; the latter is an
active target for development of hepatitis C antiviral therapies
Unlike; current flu targets (e.g., neuraminidase for Tamiflu), the
influenza RNA polymerase is highly conserved and therefore less
likely to suffer the resistance issues that current drugs face.
[0004] Recently, researchers reported the first atomic-resolution
structural details of the influenza protein RNA polymerase, a
critical enzyme for viral replication and a novel target for both
therapeutic intervention and prophylaxis during influenza outbreaks
(He, X., ct al., Nature, 2008. 454: p. 1123-6; Obayashi, E., ct
al., Nature, 2008. 454: p. 1127-31). The influenza RNA-dependent
RNA polymerase is a heterotrimer of three subunits, PA, PB1, and
PB2, with the 3.sub.10-helical N-terminal region of PB1 binding
between the "jaws" of the PA protein. The PB1 helix is thought to
be important for complex formation and nuclear transport and
inhibits influenza A viral replication by interfering with
polymerase activity. Recently, the PB2 subunit has also been shown
to play an essential role in activity of the viral polymerase
complex, for instance through contacts with the PB1 subunit. See
Sugiyama et al, EMBO Journal, 2009, 28, 1803-1811. However, little
is known about compounds capable of interfering with the binding
and activity of these proteins. In general, there remains a need
for therapeutic methods of treating viral diseases in which
RNA-dependent RNA polymerases play a role, and for compositions and
methods capable of modifying the activity such polymerases.
SUMMARY OF THE INVENTION
[0005] The present invention addresses these and other needs. In
one aspect, the present invention provides a peptidomimetic
macrocycle capable of binding to a viral RNA-dependent RNA
polymerase. Such a macrocycle may, for example, be capable of
disrupting the assembly of subunits of a viral RNA-dependent RNA
polymerase complex. In one embodiment, such a macrocycle may
compete with the binding of a peptide of the sequence
MDVNPTLLFLKVPAQ or MERIKELRNLM to said viral RNA-dependent RNA
polymerase. In one embodiment, a peptidomimetic macrocycle of the
invention comprises an amino acid sequence which is at least about
60%, 80%, 90%, or 95% identical to the amino acid sequence
MDVNPTLLFLKVPAQ (PB1) or MERIKELRNLM (PB2). Alternatively, the
amino acid sequence of said peptidomimetic macrocycle is identified
and optimized for its ability to bind to either the PB1 peptide
binding site of the PA protein or the PB2 peptide binding site of
the PB1 protein, for example through affinity selection with the PA
or PB1 target protein or by structure-based design, with such a
mechanism of action being confirmed by biophysical/structural
studies and/or competitive displacement assays with the PB1 or PB2
peptide. In some embodiments, the peptidomimetic macrocycle
comprises a helix, such as a 3.sub.10 helix or an .alpha.-helix. In
other embodiments, the peptidomimetic macrocycle comprises an
.alpha.,.alpha.-disubstituted amino acid. A peptidomimetic
macrocycle of the invention may comprise a crosslinkcr linking the
.alpha.-positions of at least two amino acids. At least one of said
two amino acids may be an .alpha.,.alpha.-disubstituted amino
acid.
[0006] In some embodiments, the peptidomimetic macrocycle has the
formula:
##STR00001##
[0007] wherein:
[0008] each A, C, D, and E is independently a natural or
non-natural amino acid;
[0009] B is a natural or non-natural amino acid, amino acid
analog,
##STR00002##
[--NH-L.sub.3-CO--], [--NH-L.sub.3-SO.sub.2--], or
[--NH-L.sub.3-];
[0010] R.sub.1 and R.sub.2 are independently --H, alkyl, alkenyl,
alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo-;
[0011] R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with
R.sub.5;
[0012] L is a macrocycle-forming linker of the formula
-L.sub.1-L.sub.2-;
[0013] L.sub.1 and L.sub.2 are independently alkylene, alkenylene,
alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene,
cycloarylene, heterocycloarylene, or
[--R.sub.4--K--R.sub.4--].sub.n, each being optionally substituted
with R.sub.5;
[0014] each R.sub.4 is alkylene, alkenylene, alkynylene,
heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene;
[0015] each K is O, S, SO, SO.sub.2, CO, CO.sub.2, or
CONR.sub.3;
[0016] each R.sub.5 is independently halogen, alkyl, --OR.sub.6,
--N(R.sub.6).sub.2, --SR.sub.6, --SOR.sub.6, --SO.sub.2R.sub.6,
--CO.sub.2R.sub.6, a fluorescent moiety, a radioisotope or a
therapeutic agent;
[0017] each R.sub.6 is independently --H, alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety,
a radioisotope or a therapeutic agent;
[0018] R.sub.7 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with R.sub.5,
or part of a cyclic structure with a D residue;
[0019] R.sub.8 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with R.sub.5,
or part of a cyclic structure with an E residue;
[0020] v and w are independently integers from 1-1000;
[0021] u, x, y and z are independently integers from 0-10; and
[0022] n is an integer from 1-5.
[0023] In other embodiments, the peptidomimetic macrocycle may
comprise a crosslinker linking a backbone amino group of a first
amino acid to a second amino acid within the peptidomimetic
macrocycle. For example, the invention provides peptidomimetic
macrocycles of the formula (IV) or (IVa):
##STR00003##
[0024] wherein:
[0025] each A, C, D, and E is independently a natural or
non-natural amino acid;
[0026] B is a natural or non-natural amino acid, amino acid
analog
##STR00004##
[--NH-L.sub.3-CO--], [--NH-L.sub.3-SO.sub.2--], or
[--NH-L.sub.3-];
[0027] R.sub.1 and R.sub.2 are independently --H, alkyl, alkenyl,
alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo-, or part
of a cyclic structure with an E residue;
[0028] R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with
R.sub.5;
[0029] L.sub.1 and L.sub.2 are independently alkylene, alkenylene,
alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene,
cycloarylene, heterocycloarylene, or
[--R.sub.4--K--R.sub.4--].sub.n, each being optionally substituted
with R.sub.5;
[0030] each R.sub.4 is alkylene, alkenylene, alkynylene,
heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene;
[0031] each K is O, S, SO, SO.sub.2, CO, CO.sub.2, or
CONR.sub.3;
[0032] each R.sub.5 is independently halogen, alkyl, --OR.sub.6,
--N(R.sub.6).sub.2, --SR.sub.6, --SOR.sub.6, --SO.sub.2R.sub.6,
--CO.sub.2R.sub.6, a fluorescent moiety, a radioisotope or a
therapeutic agent;
[0033] each R.sub.6 is independently --H, alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety,
a radioisotope or a therapeutic agent;
[0034] R.sub.7 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with
R.sub.5;
[0035] v and w are independently integers from 1-1000;
[0036] u, x, y and z are independently integers from 0-10; and
[0037] n is an integer from 1-5.
[0038] In some embodiments, x+y+z is 2, 3, 5 or 6.
[0039] Additionally, the invention provides a method of treating
influenza virus infection in a subject comprising administering to
the subject a peptidomimetic macrocycle of the invention. Also
provided is a method of preventing infection by an influenza virus
in a subject comprising administering to the subject a
peptidomimetic macrocycle of the invention, or a method of
inhibiting the activity of the RNA-dependent RNA polymerase of an
influenza virus in a subject comprising administering to the
subject such a peptidomimetic macrocycle.
INCORPORATION BY REFERENCE
[0040] All publications, patents, and patent applications mentioned
in this specification are herein incorporated by reference to the
same extent as if each individual publication, patent, or patent
application was specifically and individually indicated to be
incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0041] The novel features of the invention are set forth with
particularity in the appended claims. A better understanding of the
features and advantages of the present invention will be obtained
by reference to the following detailed description that sets forth
illustrative embodiments, in which the principles of the invention
are utilized, and the accompanying drawings of which:
[0042] FIG. 1a shows a bound PB1 helix in complex with the PA
subunit of a RNA-dependent RNA polymerase. Leu7 and Leu10 (light
color) are candidate residues for i, i+3 macrocycle formation to
stabilize a 3.sub.10 helix.
[0043] FIG. 1b shows a macrocycle derived from the sequence in FIG.
1a.
[0044] FIG. 2a shows the sequence of FIG. 1a excised from its
complex with the PA subunit or a RNA-dependent RNA polymerase.
[0045] FIG. 2b shows the macrocycle derived from the sequence in
FIG. 1b excised from its complex with the PA subunit of a
RNA-dependent RNA polymerase.
[0046] FIG. 3 describes the plasma stability of several
peptidomimetic macrocycles of the invention.
[0047] FIG. 4 shows in vivo pharmacokinetic properties of several
peptidomimetic macrocycles of the invention.
[0048] FIGS. 5a-5f illustrate in vivo pharmacokinetic properties of
peptidomimetic macrocycles of the invention.
[0049] FIG. 6 shows selected pharmacokinetic parameters for several
peptidomimetic macrocycles of the invention.
[0050] FIG. 7 illustrates pharmacokinetic properties for
intravenous and subcutaneous modes of administration for a
peptidomimetic macrocycle of the invention.
DETAILED DESCRIPTION OF THE INVENTION
[0051] As used herein, the term "macrocycle" refers to a molecule
having a chemical structure including a ring or cycle formed by at
least 9 covalently bonded atoms.
[0052] As used herein, the term "peptidomimetic macrocycle" or
"crosslinked polypeptide" refers to a compound comprising a
plurality of amino acid residues joined by a plurality of peptide
bonds and at least one macrocycle-forming linker which forms a
macrocycle between a first naturally-occurring or
non-naturally-occurring amino acid residue (or analog) and a second
naturally-occurring or non-naturally-occurring amino acid residue
(or analog) within the same molecule. Peptidomimetic macrocycle
include embodiments where the macrocycle-forming linker connects
the .alpha. carbon of the first amino acid residue (or analog) to
the .alpha. carbon of the second amino acid residue (or analog).
The peptidomimetic macrocycles optionally include one or more
non-peptide bonds between one or more amino acid residues and/or
amino acid analog residues, and optionally include one or more
non-naturally-occurring amino acid residues or amino acid analog
residues in addition to any which form the macrocycle. A
"corresponding uncrosslinked polypeptide" when referred to in the
context of a peptidomimetic macrocycle is understood to relate to a
polypeptide of the same length as the macrocycle and comprising the
equivalent natural amino acids of the wild-type sequence
corresponding to the macrocycle.
[0053] As used herein, the term "stability" refers to the
maintenance of a defined secondary structure in solution by a
peptidomimetic macrocycle of the invention as measured by circular
dichroism, NMR or another biophysical measure, or resistance to
proteolytic degradation in vitro or in vivo. Non-limiting examples
of secondary structures contemplated in this invention are helices,
.beta.-turns, and .beta.-pleated sheets. In general, the term
"helix" or "helical" is used to refer to any type of helical
secondary structure, including 3.sub.10-helices, .alpha.-helices,
and .pi.-helices.
[0054] As used herein, the term "helical stability" refers to the
maintenance of helical structure by a peptidomimetic macrocycle of
the invention as measured by circular dichroism or NMR. For
example, in some embodiments, the peptidomimetic macrocycles of the
invention exhibit at least a 1.25, 1.5, 1.75 or 2-fold increase in
helicity as determined by circular dichroism compared to a
corresponding uncrosslinked macrocycle.
[0055] The term ".alpha.-amino acid" or simply "amino acid" refers
to a molecule containing both an amino group and a carboxyl group
bound to a carbon which is designated the .alpha.-carbon. Suitable
amino acids include, without limitation, both the D- and L-isomers
of the naturally-occurring amino acids, as well as non-naturally
occurring amino acids prepared by organic synthesis or other
metabolic routes. Unless the context specifically indicates
otherwise, the term amino acid, as used herein, is intended to
include amino acid analogs.
[0056] The term "naturally occurring amino acid" refers to any one
of the twenty amino acids commonly found in peptides synthesized in
nature, and known by the one letter abbreviations A, R, N, C, D, Q,
E, G, H, I, L, K, M, F, P, S, T, W, Y and V.
[0057] The term "amino acid analog" or "non-natural amino acid"
refers to a molecule which is structurally similar to an amino acid
and which can be substituted for an amino acid in the formation of
a peptidomimetic macrocycle. Amino acid analogs include, without
limitation, compounds which are structurally identical to an amino
acid, as defined herein, except for the inclusion of one or more
additional methylene groups between the amino and carboxyl group
(e.g., .alpha.-amino .beta.-carboxy acids), or for the substitution
of the amino or carboxy group by a similarly reactive group (e.g.,
substitution of the primary amine with a secondary or tertiary
amine, or substitution or the carboxy group with an ester).
[0058] A "non-essential" amino acid residue is a residue that can
be altered from the wild-type sequence of a polypeptide (e.g., a
BH3 domain or the p53 MDM2 binding domain) without abolishing or
substantially altering its essential biological or biochemical
activity (e.g., receptor binding or activation). An "essential"
amino acid residue is a residue that, when altered from the
wild-type sequence of the polypeptide, results in abolishing or
substantially abolishing the polypeptide's essential biological or
biochemical activity.
[0059] A "conservative amino acid substitution" is one in which the
amino acid residue is replaced with an amino acid residue having a
similar side chain. Families of amino acid residues having similar
side chains have been defined in the art. These families include
amino acids with basic side chains (e.g., K, R, H), acidic side
chains (e.g., D, E), uncharged polar side chains (e.g., G, N, Q, S,
T, Y, C), nonpolar side chains (e.g., A, V, L, I, P, F, M, W),
beta-branched side chains (e.g., T, V, I) and aromatic side chains
(e.g., Y, F, W, H). Thus, a predicted nonessential amino acid
residue in a polypeptide, for example, is preferably replaced with
another amino acid residue from the same side chain family. Other
examples of acceptable substitutions are substitutions based on
isosteric considerations (e.g. norleucine for methionine) or other
properties (e.g. 2-thienylalanine for phenylalanine).
[0060] The term "member" as used herein in conjunction with
macrocycles or macrocycle-forming linkers refers to the atoms that
form or can form the macrocycle, and excludes substituent or side
chain atoms. By analogy, cyclodecane, 1,2-difluoro-decane and
1,3-dimethyl cyclodecane are all considered ten-membered
macrocycles as the hydrogen or fluoro substituents or methyl side
chains do not participate in forming the macrocycle.
[0061] The symbol "" when used as part of a molecular structure
refers to a single bond or a trans or cis double bond.
[0062] The term "amino acid side chain" refers to a moiety attached
to the .alpha.-carbon in an amino acid. For example, the amino acid
side chain for alanine is methyl, the amino acid side chain for
phenylalanine is phenylmethyl, the amino acid side chain for
cysteine is thiomethyl, the amino acid side chain for aspartate is
carboxymethyl, the amino acid side chain for tyrosine is
4-hydroxyphenylmethyl, etc. Other non-naturally occurring amino
acid side chains are also included, for example, those that occur
in nature (e.g., an amino acid metabolite) or those that are made
synthetically (e.g., an .alpha.,.alpha. di-substituted amino
acid).
[0063] The term ".alpha.,.alpha. di-substituted amino" acid refers
to a molecule or moiety containing both an amino group and a
carboxyl group bound to a carbon (the .alpha.-carbon) that is
attached to two natural or non-natural amino acid side chains.
[0064] The term "polypeptide" encompasses two or more naturally or
non-naturally-occurring amino acids joined by a covalent bond
(e.g., an amide bond). Polypeptides as described herein include
full length proteins (e.g., fully processed proteins) as well as
shorter amino acid sequences (e.g., fragments of
naturally-occurring proteins or synthetic polypeptide
fragments).
[0065] The term "macrocyclization reagent" or "macrocycle-forming
reagent" as used herein refers to any reagent which may be used to
prepare a peptidomimetic macrocycle of the invention by mediating
the reaction between two reactive groups. Reactive groups may be,
for example, an azide and alkyne, in which case macrocyclization
reagents include, without limitation, Cu reagents such as reagents
which provide a reactive Cu(I) species, such as CuBr, CuI or CuOTf,
as well as Cu(II) salts such as Cu(CO.sub.2CH.sub.3).sub.2,
CuSO.sub.4, and CuCl.sub.2 that can be converted in situ to an
active Cu(I) reagent by the addition of a reducing agent such as
ascorbic acid or sodium ascorbate. Macrocyclization reagents may
additionally include, for example, Ru reagents known in the art
such as Cp*RuCl(PPh.sub.3).sub.2, [Cp*RuCl].sub.4 or other Ru
reagents which may provide a reactive Ru(II) species. In other
cases, the reactive groups are terminal olefins. In such
embodiments, the macrocyclization reagents or macrocycle-forming
reagents are metathesis catalysts including, but not limited to,
stabilized, late transition metal carbene complex catalysts such as
Group VIII transition metal carbene catalysts. For example, such
catalysts are Ru and Os metal centers having a +2 oxidation state,
an electron count of 16 and pentacoordinated. Additional catalysts
are disclosed in Grubbs et al., "Ring Closing Metathesis and
Related Processes in Organic Synthesis" Acc. Chem. Res. 1995, 28,
446452, and U.S. Pat. No. 5,811,515. In yet other cases, the
reactive groups are thiol groups. In such embodiments, the
macrocyclization reagent is, for example, a linker functionalized
with two thiol-reactive groups such as halogen groups.
[0066] The term "halo" or "halogen" refers to fluorine, chlorine,
bromine or iodine or a radical thereof.
[0067] The term "alkyl" refers to a hydrocarbon chain that is a
straight chain or branched chain, containing the indicated number
of carbon atoms. For example, C.sub.1-C.sub.10 indicates that the
group has from 1 to 10 (inclusive) carbon atoms in it. In the
absence of any numerical designation, "alkyl" is a chain (straight
or branched) having 1 to 20 (inclusive) carbon atoms in it.
[0068] The term "alkylene" refers to a divalent alkyl (i.e.,
--R--).
[0069] The term "alkenyl" refers to a hydrocarbon chain that is a
straight chain or branched chain having one or more carbon-carbon
double bonds. The alkenyl moiety contains the indicated number of
carbon atoms. For example, C.sub.2-C.sub.10 indicates that the
group has from 2 to 10 (inclusive) carbon atoms in it. The term
"lower alkenyl" refers to a C.sub.2-C.sub.6 alkenyl chain. In the
absence of any numerical designation, "alkenyl" is a chain
(straight or branched) having 2 to 20 (inclusive) carbon atoms in
it.
[0070] The term "alkynyl" refers to a hydrocarbon chain that is a
straight chain or branched chain having one or more carbon-carbon
triple bonds. The alkynyl moiety contains the indicated number of
carbon atoms. For example, C.sub.2-C.sub.10 indicates that the
group has from 2 to 10 (inclusive) carbon atoms in it. The term
"lower alkynyl" refers to a C.sub.2-C.sub.6 alkynyl chain. In the
absence of any numerical designation, "alkynyl" is a chain
(straight or branched) having 2 to 20 (inclusive) carbon atoms in
it.
[0071] The term "aryl" refers to a 6-carbon monocyclic or 10-carbon
bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of
each ring are substituted by a substituent. Examples of aryl groups
include phenyl, naphthyl and the like. The term "arylalkyl" or the
term "aralkyl" refers to alkyl substituted with an aryl. The term
"arylalkoxy" refers to an alkoxy substituted with aryl.
[0072] "Arylalkyl" refers to an aryl group, as defined above,
wherein one of the aryl group's hydrogen atoms has been replaced
with a C.sub.1-C.sub.5 alkyl group, as defined above.
Representative examples of an arylalkyl group include, but are not
limited to, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl,
2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-propylphenyl,
3-propylphenyl, 4-propylphenyl, 2-butylphenyl, 3-butylphenyl,
4-butylphenyl, 2-pentylphenyl, 3-pentylphenyl, 4-pentylphenyl,
2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl,
2-isobutylphenyl, 3-isobutylphenyl, 4-isobutylphenyl,
2-sec-butylphenyl, 3-sec-butylphenyl, 4-sec-butylphenyl,
2-t-butylphenyl, 3-t-butylphenyl and 4-t-butylphenyl.
[0073] "Arylamido" refers to an aryl group, as defined above,
wherein one of the aryl group's hydrogen atoms has been replaced
with one or more --C(O)NH.sub.2 groups. Representative examples of
an arylamido group include 2-C(O)NH.sub.2-phenyl,
3-C(O)NH.sub.2-phenyl, 4-C(O)NH.sub.2-phenyl,
2-C(O)NH.sub.2-pyridyl, 3-C(O)NH.sub.2-pyridyl, and
4-C(O)NH.sub.2-pyridyl,
[0074] "Alkylheterocycle" refers to a C.sub.1-C.sub.5 alkyl group,
as defined above, wherein one of the C.sub.1-C.sub.5 alkyl group's
hydrogen atoms has been replaced with a heterocycle. Representative
examples of an alkylheterocycle group include, but are not limited
to, --CH.sub.2CH.sub.2-morpholine, --CH.sub.2CH.sub.2-piperidine,
--CH.sub.2CH.sub.2CH.sub.2-morpholine, and
--CH.sub.2CH.sub.2CH.sub.2-imidazole.
[0075] "Alkylamido" refers to a C.sub.1-C.sub.5 alkyl group, as
defined above, wherein one of the C.sub.1-C.sub.5 alkyl group's
hydrogen atoms has been replaced with a --C(O)NH.sub.2 group.
Representative examples of an alkylamido group include, but are not
limited to, --CH.sub.2--C(O)NH.sub.2,
--CH.sub.2CH.sub.2--C(O)NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2,
--CH.sub.2CH(C(O)NH.sub.2)CH.sub.3,
--CH.sub.2CH(C(O)NH.sub.2)CH.sub.2CH.sub.3,
--CH(C(O)NH.sub.2)CH.sub.2CH.sub.3,
--C(CH.sub.3).sub.2CH.sub.2C(O)NH.sub.2,
--CH.sub.2--CH.sub.2--NH--C(O)--CH.sub.3,
--CH.sub.2--CH.sub.2--NH--C(O)--CH.sub.3--CH.sub.3, and
--CH.sub.2--CH.sub.2--NH--C(O)--CH.dbd.CH.sub.2.
[0076] "Alkanol" refers to a C.sub.1-C.sub.5 alkyl group, as
defined above, wherein one of the C.sub.1-C.sub.5 alkyl group's
hydrogen atoms has been replaced with a hydroxyl group.
Representative examples of an alkanol group include, but are not
limited to, --CH.sub.2OH, --CH.sub.2CH.sub.2OH,
--CH.sub.2CH.sub.2CH.sub.2OH, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH,
--CH.sub.2CH(OH)CH.sub.3, --CH.sub.2CH(OH)CH.sub.2CH.sub.3,
--CH(OH)CH.sub.3 and --C(CH.sub.3).sub.2CH.sub.2OH.
[0077] "Alkylcarboxy" refers to a C.sub.1-C.sub.5 alkyl group, as
defined above, wherein one of the C.sub.1-C.sub.5 alkyl group's
hydrogen atoms has been replaced with a --COOH group.
Representative examples of an alkylcarboxy group include, but are
not limited to, --CH.sub.2COOH, --CH.sub.2CH.sub.2COOH,
--CH.sub.2CH.sub.2CH.sub.2COOH,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2COOH, --CH.sub.2CH(COOH)CH.sub.3,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2COOH,
--CH.sub.2CH(COOH)CH.sub.2CH.sub.3, --CH(COOH)CH.sub.2CH.sub.3 and
--C(CH.sub.3).sub.2CH.sub.2COOH.
[0078] The term "cycloalkyl" as employed herein includes saturated
and partially unsaturated cyclic hydrocarbon groups having 3 to 12
carbons, preferably 3 to 8 carbons, and more preferably 3 to 6
carbons, wherein the cycloalkyl group additionally is optionally
substituted. Some cycloalkyl groups include, without limitation,
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl, and cyclooctyl.
[0079] The term "heteroaryl" refers to an aromatic 5-8 membered
monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic
ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms
if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms
selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9
heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic,
respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring are
substituted by a substituent. Examples of heteroaryl groups include
pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl,
thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the
like.
[0080] The term "heteroarylalkyl" or the term "heteroaralkyl"
refers to an alkyl substituted with a heteroaryl. The term
"heteroarylalkoxy" refers to an alkoxy substituted with
heteroaryl.
[0081] The term "heteroarylalkyl" or the term "heteroaralkyl"
refers to an alkyl substituted with a heteroaryl. The term
"heteroarylalkoxy" refers to an alkoxy substituted with
heteroaryl.
[0082] The term "heterocyclyl" refers to a nonaromatic 5-8 membered
monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic
ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms
if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms
selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9
heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic,
respectively), wherein 0, 1, 2 or 3 atoms of each ring are
substituted by a substituent. Examples of heterocyclyl groups
include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl,
tetrahydrofuranyl, and the like.
[0083] The term "substituent" refers to a group replacing a second
atom or group such as a hydrogen atom on any molecule, compound or
moiety. Suitable substituents include, without limitation, halo,
hydroxy, mercapto, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl,
aralkyl, alkoxy, thioalkoxy, aryloxy, amino, alkoxycarbonyl, amido,
carboxy, alkanesulfonyl, alkylcarbonyl, and cyano groups.
[0084] In some embodiments, the compounds of this invention contain
one or more asymmetric centers and thus occur as racemates and
racemic mixtures, single enantiomers, individual diastereomers and
diastereomeric mixtures. All such isomeric forms of these compounds
are included in the present invention unless expressly provided
otherwise. In some embodiments, the compounds of this invention are
also represented in multiple tautomeric forms, in such instances,
the invention includes all tautomeric forms of the compounds
described herein (e.g., if alkylation of a ring system results in
alkylation at multiple sites, the invention includes all such
reaction products). All such isomeric forms of such compounds are
included in the present invention unless expressly provided
otherwise. All crystal forms of the compounds described herein are
included in the present invention unless expressly provided
otherwise.
[0085] As used herein, the terms "increase" and "decrease" mean,
respectively, to cause a statistically significantly (i.e.,
p<0.1) increase or decrease of at least 5%.
[0086] As used herein, the recitation of a numerical range for a
variable is intended to convey that the invention may be practiced
with the variable equal to any of the values within that range.
Thus, for a variable which is inherently discrete, the variable is
equal to any integer value within the numerical range, including
the end-points of the range. Similarly, for a variable which is
inherently continuous, the variable is equal to any real value
within the numerical range, including the end-points of the range.
As an example, and without limitation, a variable which is
described as having values between 0 and 2 takes the values 0, 1 or
2 if the variable is inherently discrete, and takes the values 0.0,
0.1, 0.01, 0.001, or any other real values.ltoreq.0 and .ltoreq.2
if the variable is inherently continuous.
[0087] As used herein, unless specifically indicated otherwise, the
word "or" is used in the inclusive sense of "and/or" and not the
exclusive sense of "either/or."
[0088] The term "on average" represents the mean value derived from
performing at least three independent replicates for each data
point.
[0089] The term "biological activity" encompasses structural and
functional properties of a macrocycle of the invention. Biological
activity is, for example, structural stability, helicity
(including, e.g. alpha-helicity), affinity for a target, resistance
to proteolytic degradation, cell penetrability, intracellular
stability, in vivo stability, or any combination thereof.
[0090] The details of one or more particular embodiments of the
invention are set forth in the accompanying drawings and the
description below. Other features, objects, and advantages of the
invention will be apparent from the description and drawings, and
from the claims.
Design of Peptidomimetic Macrocycles
[0091] In general, peptidomimetic macrocycles are prepared that
target or interact with proteins that a virus needs for infection
or replication within a host cell. Such viruses may be, for
example, influenza viruses belonging to Orthomyxoviridae family of
viruses. This family also includes Thogoto viruses and
Dhoriviruses. There are several types and subtypes of influenza
viruses known, which infect humans and other species. Influenza
type A viruses infect people, birds, pigs, horses, seals and other
animals, but wild birds are the natural hosts for these viruses.
Influenza type A viruses are divided into subtypes and named on the
basis of two proteins on the surface of the virus: hemagglutinin
(HA) and neuraminidase (NA). For example, an "H7N2 virus"
designates an influenza A subtype that has an HA 7 protein and an
NA 2 protein. Similarly an "H5N1" virus has an HA 5 protein and an
NA 1 protein. There are 16 known HA subtypes and 9 known NA
subtypes. Many different combinations of HA and NA proteins are
possible. Only some influenza A subtypes (i.e., H1N1, H1N2, and
H3N2) are currently in general circulation among people. Other
subtypes are found most commonly in other animal species. For
example, H7N7 and H3N8 viruses cause illness in horses, and H3N8
also has recently been shown to cause illness in dogs
(http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm).
[0092] Antiviral agents according to the invention can be used to
protect high-risk groups (hospital units, institutes caring for
elderly, immuno-suppressed individuals), and on a cast by case
basis. A potential use for antiviral agents is to limit the spread
and severity of the future pandemics whether caused by avian H5N1
or other strains of influenza virus. Avian influenza A viruses of
the subtypes H5 and H7, including H5N1, H7N7, and H7N3 viruses,
have been associated with high pathogenicity, and human infection
with these viruses have ranged from mild (H7N3, H7N7) to severe and
fatal disease (H7N7, H5N1). Human illness due to infection with low
pathogenicity viruses has been documented, including very mild
symptoms (e.g., conjunctivitis) to influenza-like illness. Examples
of low pathogenicity viruses that have infected humans include
H7N7, H9N2, and H7N2.
(http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm).
[0093] Influenza B viruses are usually found in humans but can also
infect seals. Unlike influenza A viruses, these viruses are not
classified according to subtype. Influenza B viruses can cause
morbidity and mortality among humans, but in general are associated
with less severe epidemics than influenza A viruses. Although
influenza type B viruses can cause human epidemics, they have not
caused pandemics.
(http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm).
[0094] Influenza type C viruses cause mild illness in humans and do
not cause epidemics or pandemics. These viruses can also infect
dogs and pigs. These viruses are not classified according to
subtype.
(http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm).
[0095] Influenza viruses differ from each other in respect to cell
surface receptor specificity and cell tropism, however they use
common entry pathways. Charting these pathways and identification
of host cell proteins involved in virus influenza transmission,
entry, replication, biosynthesis, assembly, or exit allows the
development of general agents against existing and emerging strains
of influenza. The agents may also prove useful against unrelated
viruses that use similar pathways. For example, the agents may
protect airway epithelial cells against a number of different
viruses in addition to influenza viruses.
[0096] In one embodiment the targeted virus is an adenovirus.
Adenoviruses most commonly cause respiratory illness; symptoms of
respiratory illness caused by adenovirus infection range from the
common cold syndrome to pneumonia, croup, and bronchitis. Patients
with compromised immune systems are especially susceptible to
severe complications of adenovirus infection. Acute respiratory
disease (ARD), first recognized among military recruits during
World War II, can be caused by adenovirus infections during
conditions of crowding and stress. Adenoviruses are medium-sized
(90-100 nm), nonenveloped icosohedral viruses containing
double-stranded DNA. There are 49 immunologically distinct types (6
subgenera: A through F) that can cause human infections.
Adenoviruses are unusually stable to chemical or physical agents
and adverse pH conditions, allowing for prolonged survival outside
of the body. Some adenoviruses, such as AD2 and Ad5 (species C) use
clathrin mediated endocytosis and macropinocytosis for infectious
entry. Other adenoviruses, such as Ad3 (species B) use dynamin
dependent endocytosis and macropinocytosis for infectious
entry.
[0097] In one embodiment the targeted virus is a respiratory
syncytial virus (RSV). RSV is the most common cause of
bronchiolitis and pneumonia among infants and children under 1 year
of age. Illness begins most frequently with fever, runny nose,
cough, and sometimes wheezing. During their first RSV infection,
between 25% and 40% of infants and young children have signs or
symptoms of bronchiolitis or pneumonia, and 0.5% to 2% require
hospitalization. Most children recover from illness in 8 to 15
days. The majority of children hospitalized for RSV infection are
under 6 months of age. RSV also causes repeated infections
throughout life, usually associated with moderate-to-severe
cold-like symptoms; however, severe lower respiratory tract disease
may occur at any age, especially among the elderly or among those
with compromised cardiac, pulmonary, or immune systems. RSV is a
negative-sense, enveloped RNA virus. The virion is variable in
shape and size (average diameter of between 120 and 300 nm), is
unstable in the environment (surviving only a few hours on
environmental surfaces), and is readily inactivated with soap and
water and disinfectants.
[0098] In one embodiment the targeted virus is a human
parainfluenza virus (HPIV). HPIVs arc second to respiratory
syncytial virus (RSV) as a common cause of lower respiratory tract
disease in young children. Similar to RSV, HPIVs can cause repeated
infections throughout life, usually manifested by an upper
respiratory tract illness (e.g., a cold and/or sore throat). HPIVs
can also cause serious lower respiratory tract disease with repeat
infection (e.g., pneumonia, bronchitis, and bronchiolitis),
especially among the elderly, and among patients with compromised
immune systems. Each of the four HPIVs has different clinical and
epidemiologic features. The most distinctive clinical feature of
HPIV-1 and HPIV-2 is croup (i.e., laryngotracheobronchitis); HPIV-1
is the leading cause of croup in children, whereas HPIV-2 is less
frequently detected. Both HPIV-1 and -2 can cause other upper and
lower respiratory tract illnesses. HPIV-3 is more often associated
with bronchiolitis and pneumonia. HPIV-4 is infrequently detected,
possibly because it is less likely to cause severe disease. The
incubation period for HPIVs is generally from 1 to 7 days. HPIVs
are negative-sense, single-stranded RNA viruses that possess fusion
and hemagglutinin-neuraminidase glycoprotein "spikes" on their
surface. There are four serotypes types of HPIV (1 through 4) and
two subtypes (4a and 4b). The virion varies in size (average
diameter between 150 and 300 nm) and shape, is unstable in the
environment (surviving a few hours on environmental surfaces), and
is readily inactivated with soap and water.
[0099] In one embodiment the targeted virus is a coronavirus.
Coronavirus is a genus of animal virus belonging to the family
Coronaviridae. Coronaviruses are enveloped viruses with a
positive-sense single-stranded RNA genome and a helical symmetry.
The genomic size of coronaviruses ranges from approximately 16 to
31 kilobases, extraordinarily large for an RNA virus. The name
"coronavirus" is derived from the Latin corona, meaning crown, as
the virus envelope appears under electron microscopy to be crowned
by a characteristic ring of small bulbous structures. This
morphology is actually formed by the viral spike peplomers, which
are proteins that populate the surface of the virus and determine
host tropism. Coronaviruses are grouped in the order Nidovirales,
named for the Latin nidus, meaning nest, as all viruses in this
order produce a 3' co-terminal nested set of subgenomic mRNA's
during infection. Proteins that contribute to the overall structure
of all coronaviruses are the spike, envelope, membrane and
nucleocapsid. In the specific case of SARS a defined
receptor-binding domain on S mediates the attachment of the virus
to its cellular receptor, angiotensin-converting enzyme 2.
[0100] In one embodiment the targeted virus is a rhinovirus.
Rhinovirus (from the Greek rhin-, which means "nose") is a genus of
the Picornaviridae family of viruses. Rhinoviruses are the most
common viral infective agents in humans, and a causative agent of
the common cold. There are over 105 serologic virus types that
cause cold symptoms, and rhinoviruses are responsible for
approximately 50% of all cases. Rhinoviruses have single-stranded
positive sense RNA genomes of between 7.2 and 8.5 kb in length. At
the 5' end of the genome is a virus-encoded protein, and like
mammalian mRNA, there is a 3' poly-A tail. Structural proteins are
encoded in the 5' region of the genome and non structural at the
end. This is the same for all picornaviruses. The viral particles
themselves are not enveloped and are icosahedral in structure.
[0101] Any secondary structure of a viral protein (or of a host
cell protein involved in viral infectivity) can form the basis of
the methods of the invention. For example, a viral proteins
comprising a secondary structure which is a helix may be used to
design peptidomimetic macrocycles based on said helix.
[0102] In one embodiment, the peptidomimetic macrocycle of the
invention is designed based on the PB1 or PB2 sequence of an
influenza virus. The PB1 sequence is highly conserved across all
known strains of influenza A virus, which may result in less drug
resistance should than that observed with the current standard of
care. An alignment of the first 25 N-terminal amino acids of PB1
from the NCBI data bank's 2,485 influenza A virus strains (Ghanem,
2007) demonstrates the remarkable sequence conservation in the PA
interaction domain of PB1. Therefore, antiviral therapies based on
the PB1 sequence may block most if not all, influenza A virus
strains. Additionally, sequence modification of a peptidomimetic
macrocycle based on these few variations in PB1 may enable an
antiviral cocktail of PB1 inhibitors to eliminate resistance due to
escape mutants.
[0103] A non-limiting exemplary list of sequences suitable for
macrocyclization as well as macrocyclic peptides for use in the
present invention is given below:
TABLE-US-00001 TABLE 1a Exemplary PB1 peptidomimetic macrocycles of
the invention. Influenza PB1 Sequences For Macrocyclization (bold =
critical residue; X = cross-linked amino acid) 1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 Ac-- Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val
Pro Ala Gln --NH2 Wt, backbone H-- bonds Ac-- Met Asp Val Asn Pro
Thr Leu Leu Phe Leu Lys Val Pro Ala Gln --NH2 wt, side- chain H--
bonds contacts Ac-- Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val
Pro Ala Gln --NH2 wt, side- chain hydrophobic contacts Ac-- Met/
Asp Val Asn X Thr/ Leu X Phe Leu Lys Val Pro/ Ala/ Gln/ --NH2
i--> i + 3 Nle Aib Aib Aib Arg x-link #1 Ac-- Met/ Asp Val Asn
Pro/ X Leu Leu X Leu Lys Val Pro/ Ala/ Gln/ --NH2 i--> i + 3 Nle
Aib Aib Aib Arg x-link #2 Ac-- Met/ Asp Val Asn Pro/ Thr/ X Leu Phe
X Lys Val Pro/ Ala/ Gln/ --NH2 i--> i + 3 Nle Aib Aib Aib Aib
Arg x-link #3 Ac-- Met/ Asp Val Asn Pro/ Thr/ Leu Leu X Leu Lys X
Pro/ Ala/ Gln/ --NH2 i--> i + 3 Nle Aib Aib Aib Aib Arg x-link
#4 Ac-- Met/ Asp Val Asn Pro/ Thr/ Leu Leu Phe X Lys Val X Ala/
Gln/ --NH2 i--> i + 3 Nle Aib Aib Aib Arg x-link #5 Ac-- Met/
Asp Val Asn Pro/ Thr/ Leu Leu Phe Leu Lys X Pro/ Ala/ X --NH2 i
--> i + 3 Nle Aib Aib Aib Aib x-link #6 X Thr/ Leu Leu Phe Leu
Lys Val Pro/ Ala/ Gln/ --NH2 Formula Aib Aib Aib Arg IV x- link
#1
TABLE-US-00002 Charge PB1 Peptidomimetic Macrocycles (bold =
mutated residue; $ = S5-olefin amino acid; % = Formula IV x-link)
at pH 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 7.4 Ac-- Met Asp Val Asn
$ Thr Leu $ Phe Leu Lys Val Pro Ala Gln --NH2 0 Ac-- Nle Asp Val
Asn $ Aib Leu $ Phe Leu Lys Val Aib Aib Gln --NH2 0 Ac-- Nle Asp
Val Asn $ Aib Leu $ Phe Leu Lys Val Aib Aib Arg --NH2 1 Ac-- Met
Asp Val Asn Pro $ Leu Leu $ Leu Lys Val Pro Ala Gln --NH2 0 Ac--
Nle Asp Val Asn Aib $ Leu Leu $ Leu Lys Val Aib Aib Gln --NH2 0
Ac-- Nle Asp Val Asn Aib $ Leu Leu $ Leu Lys Val Aib Aib Arg --NH2
1 Ac-- Met Asp Val Asn Pro Thr $ Leu Phe $ Lys Val Pro Ala Gln
--NH2 0 Ac-- Nle Asp Val Asn Aib Aib $ Leu Phe $ Lys Val Aib Aib
Gln --NH2 0 Ac-- Nle Asp Val Asn Aib Aib $ Leu Phe $ Lys Val Aib
Aib Arg --NH2 1 Ac-- Met Asp Val Asn Pro Thr Leu Leu $ Leu Lys $
Pro Ala Gln --NH2 0 Ac-- Nle Asp Val Asn Aib Aib Leu Leu $ Leu Lys
$ Aib Aib Gln --NH2 0 Ac-- Nle Asp Val Asn Aib Aib Leu Leu $ Leu
Lys $ Aib Aib Arg --NH2 1 Ac-- Met Asp Val Asn Pro Thr Leu Leu Phe
$ Lys Val $ Ala Gln --NH2 0 Ac-- Nle Asp Val Asn Aib Aib Leu Leu
Phe $ Lys Val $ Aib Gln --NH2 0 Ac-- Nle Asp Val Asn Aib Aib Leu
Leu Phe $ Lys Val $ Aib Arg --NH2 1 Ac-- Met Asp Val Asn Pro Thr
Leu Leu Phe Leu Lys $ Pro Ala $ --NH2 0 Ac-- Nle Asp Val Asn Aib
Aib Leu Leu Phe Leu Lys $ Aib Aib $ --NH2 0 % Thr Leu Leu Phe Leu
Lys Val Pro Ala Gln --NH2 1 % Aib Leu Leu Phe Leu Lys Val Aib Aib
Gln --NH2 1 % Aib Leu Leu Phe Leu Lys Val Aib Aib Arg --NH2 2
TABLE-US-00003 TABLE 1b Exemplary PB2 peptidomimetic macrocycles of
the invention Influenza PB2 Sequences For Macrocyclization (bold =
critical residue; X = cross-linked amino acid) 1 2 3 4 5 6 7 8 9 10
11 Design Notes Ac-- Met/Nle Glu Arg Ile Lys Glu Leu Arg Asn Leu
Met/Nle --NH2 wt, side- chain H-- bonds contacts Ac-- Met/Nle Glu
Arg Ile Lys Glu Leu Arg Asn Leu Met/Nle --NH2 wt, side- chain
hydrophobic contacts Ac-- X Glu Arg Ile X Glu Leu Arg Asn Leu
Met/Nle --NH2 i--> i + 4 x- link #1 Ac-- Met/Nle Glu Arg Ile X
Glu Leu Arg X Leu Met/Nle --NH2 i--> i + 4 x- link #2 Ac--
Met/Nle X Arg Ile Lys X Leu Arg Asn Leu Met/Nle --NH2 i--> i + 4
x- link #3 Ac-- X Glu Arg Ile Lys Glu Leu X Asn Leu Met/Nle --NH2
i--> i + 7 x- link #1 Ac-- Met/Nle X Arg Ile Lys Glu Leu Arg X
Leu Met/Nle --NH2 i--> i + 7 x- link #2 X Met/Nle Glu XArg He
Lys Glu Leu Arg Asn Leu Met/Nle --NH2 Formula IV x-link #1 X
Met/Nle Glu XAla Ile Lys Glu Leu Arg Asn Leu Met/Nle --NH2 Formula
IV x-link #2 X Met/Nle Glu XGly Ile Lys Glu Leu Arg Asn Leu Met/Nle
--NH2 Formula IV x-link #3
TABLE-US-00004 Influenza PB2 Peptidomimetic Macrocycles (bold =
mutated residue; S5 = S5-olefin aa; R8 = R8-olefin aa; % = Formula
IV x-link) Charge at 1 2 3 4 5 6 7 8 9 10 11 pH 7.4 Ac-- S5 Glu Arg
Ile S5 Glu Leu Arg Asn Leu Met --NH2 0 Ac-- Met Glu Arg Ile S5 Glu
Leu Arg S5 Leu Met --NH2 0 Ac-- Met S5 Arg Ile Lys S5 Leu Arg Asn
Leu Met --NH2 3 Ac-- R8 Glu Arg Ile Lys Glu Leu S5 Asn Leu Met
--NH2 0 Ac-- Met R8 Arg Ile Lys Glu Leu Arg S5 Leu Met --NH2 2 %
Met Glu % Arg Ile Lys Glu Leu Arg Asn Leu Met --NH2 1 % Met Glu %
Ala Ile Lys Glu Leu Arg Asn Leu Met --NH2 0 % Met Glu % Gly Ile Lys
Glu Leu Arg Asn Leu Met --NH2 0 Ac-- S5 Glu Arg Ile S5 Glu Leu Arg
Asn Leu Nle --NH2 0 Ac-- Nle Glu Arg Ile S5 Glu Leu Arg S5 Leu Nle
--NH2 0 Ac-- Nle S5 Arg Ile Lys S5 Leu Arg Asn Leu Nle --NH2 3 Ac--
R8 Glu Arg Ile Lys Glu Leu S5 Asn Leu Nle --NH2 0 Ac-- Nle R8 Arg
Ile Lys Glu Leu Arg S5 Leu Nle --NH2 2 % Nle Glu % Arg Ile Lys Glu
Leu Arg Asn Leu Nle --NH2 1 % Nle Glu % Ala Ile Lys Glu Leu Arg Asn
Leu Nle --NH2 0 % Nle Glu % Gly Ile Lys Glu Leu Arg Asn Leu Nle
--NH2 0
[0104] Peptidomimetic Macrocycles of the Invention
[0105] In some embodiments, a peptidomimetic macrocycle of the
invention has the Formula (I):
##STR00005##
[0106] wherein:
[0107] each A, C, D, and E is independently a natural or
non-natural amino acid;
[0108] B is a natural or non-natural amino acid, amino acid
analog
##STR00006##
[--NH-L.sub.3-CO--], [--NH-L.sub.3-SO.sub.2--], or
[--NH-L.sub.3-];
[0109] R.sub.1 and R.sub.2 are independently --H, alkyl, alkenyl,
alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo-;
[0110] R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with
R.sub.5;
[0111] L is a macrocycle-forming linker of the formula
-L.sub.1-L.sub.2-;
[0112] L.sub.1 and L.sub.2 are independently alkylene, alkenylene,
alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene,
cycloarylene, heterocycloarylene, or
[--R.sub.4--K--R.sub.4--].sub.n, each being optionally substituted
with R.sub.5;
[0113] each R.sub.4 is alkylene, alkenylene, alkynylene,
heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene;
[0114] each K is O, S, SO, SO.sub.2, CO, CO.sub.2, or
CONR.sub.3;
[0115] each R.sub.5 is independently halogen, alkyl, --OR.sub.6,
--N(R.sub.6).sub.2, --SR.sub.6, --SOR.sub.6, --SO.sub.2R.sub.6,
--CO.sub.2R.sub.6, a fluorescent moiety, a radioisotope or a
therapeutic agent;
[0116] each R.sub.6 is independently --H, alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety,
a radioisotope or a therapeutic agent;
[0117] R.sub.7 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with R.sub.5,
or part of a cyclic structure with a D residue;
[0118] R.sub.8 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with R.sub.5,
or part of a cyclic structure with an E residue;
[0119] v and w are independently integers from 1-1000;
[0120] u, x, y and z are independently integers from 0-10; and
[0121] n is an integer from 1-5.
[0122] In one example, at least one of R.sub.1 and R.sub.2 is
alkyl, unsubstituted or substituted with halo-. In another example,
both R.sub.1 and R.sub.2 are independently alkyl, unsubstituted or
substituted with halo-. In some embodiments, at least one of
R.sub.1 and R.sub.2 is methyl. In other embodiments, R.sub.1 and
R.sub.2 are methyl.
[0123] In some embodiments of the invention, x+y+z is at least 2.
In other embodiments of the invention, x+y+z is 1, 2, 3, 4, 5, 6,
7, 8, 9 or 10. Each occurrence of A, B, C, D or E in a macrocycle
or macrocycle precursor of the invention is independently selected.
For example, a sequence represented by the formula [A].sub.x, when
x is 3, encompasses embodiments where the amino acids are not
identical, e.g. Gln-Asp-Ala as well as embodiments where the amino
acids are identical, e.g. Gln-Gln-Gln. This applies for any value
of x, y, or z in the indicated ranges. Similarly, when u is greater
than 1, each compound of the invention may encompass peptidomimetic
macrocycles which are the same or different. For example, a
compound of the invention may comprise peptidomimetic macrocycles
comprising different linker lengths or chemical compositions.
[0124] In some embodiments, the peptidomimetic macrocycle of the
invention comprises a secondary structure which is a helix and
R.sub.8 is --H, allowing intrahelical hydrogen bonding. In some
embodiments, at least one of A, B, C, D or E is an
.alpha.,.alpha.-disubstituted amino acid. In one example, B is an
.alpha.,.alpha.-disubstituted amino acid. For instance, at least
one of A, B, C, D or E is 2-aminoisobutyric acid. In other
embodiments, at least one of A, B, C, D or E is
##STR00007##
[0125] In other embodiments, the length of the macrocycle-forming
linker L as measured from a first C.alpha. to a second C.alpha. is
selected to stabilize a desired secondary peptide structure, such
as a helix formed by residues of the peptidomimetic macrocycle
including, but not necessarily limited to, those between the first
C.alpha. to a second C.alpha..
[0126] In one embodiment, the peptidomimetic macrocycle of Formula
(I) is:
##STR00008##
wherein each R.sub.1 and R.sub.2 is independently independently H,
alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with
halo.
[0127] In related embodiments, the peptidomimetic macrocycle of
Formula (I) is:
##STR00009##
[0128] Exemplary embodiments of the macrocycle-forming linker L are
shown below.
##STR00010##
[0129] In some embodiments, the peptidomimetic macrocycles of the
invention have the Formula (II):
##STR00011##
[0130] wherein:
[0131] each A, C, D, and E is independently a natural or
non-natural amino acid;
[0132] B is a natural or non-natural amino acid, amino acid
analog,
##STR00012##
[--NH-L.sub.3-CO--], [--NH-L.sub.3-SO.sub.2--], or
[--NH-L.sub.3-];
[0133] R.sub.1 and R.sub.2 are independently H, alkyl, alkenyl,
alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo;
[0134] R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with
R.sub.5;
[0135] L is a macrocycle-forming linker of the formula
##STR00013##
[0136] L.sub.1, L.sub.2 and L.sub.3 are independently alkylene,
alkenylene, alkynylene, heteroalkylene, cycloalkylene,
heterocycloalkylene, cycloarylene, heterocycloarylene, or
[--R.sub.4--K--R.sub.4--].sub.n, each being optionally substituted
with R.sub.5;
[0137] each R.sub.4 is alkylene, alkenylene, alkynylene,
heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene;
[0138] each K is O, S, SO, SO.sub.2, CO, CO.sub.2, or
CONR.sub.3;
[0139] each R.sub.5 is independently halogen, alkyl, --OR.sub.6,
--N(R.sub.6).sub.2, --SR.sub.6, --SOR.sub.6, --SO.sub.2R.sub.6,
--CO.sub.2R.sub.6, a fluorescent moiety, a radioisotope or a
therapeutic agent;
[0140] each R.sub.6 is independently --H, alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety,
a radioisotope or a therapeutic agent;
[0141] R.sub.7 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with R.sub.5,
or part of a cyclic structure with a D residue;
[0142] R.sub.8 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with R.sub.5,
or part of a cyclic structure with an F residue;
[0143] v and w are independently integers from 1-1000;
[0144] u, x, y and z are independently integers from 0-10; and
[0145] n is an integer from 1-5.
[0146] In one example, at least one of R.sub.1 is alkyl,
unsubstituted or substituted with halo-. In another example, both
R.sub.1 and R.sub.2 are independently alkyl, unsubstituted or
substituted with halo. In some embodiments, at least one of R.sub.1
and R.sub.2 is methyl. In other embodiments, R.sub.1 and R.sub.2
are methyl.
[0147] In some embodiments of the invention, x+y+z is at least 2.
In other embodiments of the invention, x+y+z is 1, 2, 3, 4, 5, 6,
7, 8, 9 or 10. Each occurrence of A, B, C, D or E in a macrocycle
or macrocycle precursor of the invention is independently selected.
For example, a sequence represented by the formula [A].sub.x, when
x is 3, encompasses embodiments where the amino acids are not
identical, e.g. Gln Asp Ala as well as embodiments where the amino
acids are identical, e.g. Gln Gln Gln. This applies for any value
of x, y, or z in the indicated ranges.
[0148] In some embodiments, the peptidomimetic macrocycle of the
invention comprises a secondary structure which is a helix and
R.sub.8 is --H, allowing intrahelical hydrogen bonding. In some
embodiments, at least one of A, B, C, D or E is an
.alpha.,.alpha.-disubstituted amino acid. In one example, B is an
.alpha.,.alpha.-disubstituted amino acid. For instance, at least
one of A, B, C, D or E is 2-aminoisobutyric acid. In other
embodiments, at least one of A, B, C, D or E is
##STR00014##
[0149] In other embodiments, the length of the macrocycle-forming
linker L as measured from a first C.alpha. to a second C.alpha. is
selected to stabilize a desired secondary peptide structure, such
as a helix formed by residues of the peptidomimetic macrocycle
including, but not necessarily limited to, those between the first
C.alpha. to a second C.alpha..
[0150] Exemplary embodiments of the macrocycle-forming linker L are
shown below.
##STR00015## ##STR00016## ##STR00017## ##STR00018## ##STR00019##
##STR00020## ##STR00021## ##STR00022## ##STR00023##
##STR00024##
[0151] In other embodiments, the invention provides peptidomimetic
macrocycles of Formula (III):
##STR00025##
[0152] wherein:
[0153] each A, C, D, and F is independently a natural or
non-natural amino acid;
[0154] B is a natural or non-natural amino acid, amino acid
analog,
##STR00026##
[--NH-L.sub.4-CO--], [--NH-L.sub.4-SO.sub.2--], or
[--NH-L.sub.4-];
[0155] R.sub.1 and R.sub.2 are independently --H, alkyl, alkenyl,
alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo-;
[0156] R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl,
cycloaryl, or heterocycloaryl, unsubstituted or substituted with
R.sub.5;
[0157] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are independently
alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene,
heterocycloalkylene, cycloarylene, heterocycloarylene or
[--R.sub.4--K--R.sub.4--].sub.n, each being unsubstituted or
substituted with R.sub.5;
[0158] K is O, S, SO, SO.sub.2, CO, CO.sub.2, or CONR.sub.3;
[0159] each R.sub.4 is alkylene, alkenylene, alkynylene,
heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene;
[0160] each R.sub.5 is independently halogen, alkyl, --OR.sub.6,
--N(R.sub.6).sub.2, --SR.sub.6, --SOR.sub.6, --SO.sub.2R.sub.6,
--CO.sub.2R.sub.6, a fluorescent moiety, a radioisotope or a
therapeutic agent;
[0161] each R.sub.6 is independently --H, alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety,
a radioisotope or a therapeutic agent;
[0162] R.sub.7 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, unsubstituted or substituted with
R.sub.5, or part of a cyclic structure with a D residue;
[0163] R.sub.8 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, unsubstituted or substituted with
R.sub.5, or part of a cyclic structure with an E residue;
[0164] v and w are independently integers from 1-1000;
[0165] u, x, y and z are independently integers from 0-10; and
[0166] n is an integer from 1-5.
[0167] In one example, at least one of R.sub.1 and R.sub.2 is
alkyl, unsubstituted or substituted with halo-. In another example,
both R.sub.1 and R.sub.2 are independently alkyl, unsubstituted or
substituted with halo-. In some embodiments, at least one of
R.sub.1 and R.sub.2 is methyl. In other embodiments, R.sub.1 and
R.sub.2 are methyl.
[0168] In some embodiments of the invention, x+y+z is at least 2.
In other embodiments of the invention, x+y+z is 3, 4, 5, 6, 7, 8, 9
or 10. Each occurrence of A, B, C, D or E in a macrocycle or
macrocycle precursor of the invention is independently selected.
For example, a sequence represented by the formula [A].sub.x, when
x is 3, encompasses embodiments where the amino acids are not
identical, e.g. Gln-Asp-Ala as well as embodiments where the amino
acids are identical, e.g. Gln-Gln-Gln. This applies for any value
of x, y, or z in the indicated ranges.
[0169] In some embodiments, the peptidomimetic macrocycle of the
invention comprises a secondary structure which is a helix and
R.sub.8 is --H, allowing intrahelical hydrogen bonding. In some
embodiments, at least one of A, B, C, D or E is an
.alpha.,.alpha.-disubstituted amino acid. In one example, B is an
.alpha.,.alpha.-disubstituted amino acid. For instance, at least
one of A, B, C, D or E is 2-aminoisobutyric acid. In other
embodiments, at least one of A, B, C, D or E is
##STR00027##
[0170] In other embodiments, the length of the macrocycle-forming
linker [-L.sub.1-S-L.sub.2-S-L.sub.3-] as measured from a first
C.alpha. to a second C.alpha. is selected to stabilize a desired
secondary peptide structure, such as a helix (including, but not
limited to a 3.sub.10 helix or an .alpha.-helix) formed by residues
of the peptidomimetic macrocycle including, but not necessarily
limited to, those between the first C.alpha. to a second
C.alpha..
[0171] Macrocycles or macrocycle precursors are synthesized, for
example, by solution phase or solid-phase methods, and can contain
both naturally-occurring and non-naturally-occurring amino acids.
See, for example, Hunt, "The Non-Protein Amino Acids" in Chemistry
and Biochemistry of the Amino Acids, edited by G. C. Barrett,
Chapman and Hall, 1985. In some embodiments, the thiol moieties are
the side chains of the amino acid residues L-cysteine, D-cysteine,
.alpha.-methyl-L cysteine, .alpha.-methyl-D-cysteine,
L-homocysteine, D-homocysteine, .alpha.-methyl-L-homocysteine or
.alpha.-methyl-D-homocysteine. A bis-alkylating reagent is of the
general formula X-L.sub.2-Y wherein L.sub.2 is a linker moiety and
X and Y are leaving groups that are displaced by --SH moieties to
form bonds with L.sub.2. In some embodiments, X and Y are halogens
such as I, Br, or Cl.
[0172] In other embodiments, D and/or E in the compound of Formula
I, II or III are further modified in order to facilitate cellular
uptake. In some embodiments, lipidating or PEGylating a
peptidomimetic macrocycle facilitates cellular uptake, increases
bioavailability, increases blood circulation, alters
pharmacokinetics, decreases immunogenicity and/or decreases the
needed frequency of administration.
[0173] In other embodiments, at least one of [D] and [E] in the
compound of Formula I, II or III represents a moiety comprising an
additional macrocycle-forming linker such that the peptidomimetic
macrocycle comprises at least two macrocycle-forming linkers. In a
specific embodiment, a peptidomimetic macrocycle comprises two
macrocycle-forming linkers.
[0174] In the peptidomimetic macrocycles of the invention, any of
the macrocycle-forming linkers described herein may be used in any
combination with any of the sequences shown in Tables 1-4 and also
with any of the R substituents indicated herein.
[0175] In some embodiments, the peptidomimetic macrocycle of the
invention comprises at least one helical motif such as a 3.sub.10
or an .alpha.-helix motif. For example, A, B and/or C in the
compound of Formula I, II or III include one or more helices. As a
general matter, helices include between 3 and 4 amino acid residues
per turn. In some embodiments, the helix of the peptidomimetic
macrocycle includes 1 to 5 turns and, therefore, 3 to 20 amino acid
residues. In specific embodiments, the helix includes 1 turn, 2
turns, 3 turns, 4 turns, or 5 turns. In some embodiments, the
macrocycle-forming linker stabilizes a helix motif included within
the peptidomimetic macrocycle. Thus, in some embodiments, the
length of the macrocycle-forming linker L from a first C.alpha. to
a second C.alpha. is selected to increase the stability of a helix.
In some embodiments, the macrocycle-forming linker spans from 1
turn to 5 turns of the helix. In some embodiments, the
macrocycle-forming linker spans approximately 1 turn, 2 turns, 3
turns, 4 turns, or 5 turns of the helix. In some embodiments, the
length of the macrocycle-forming linker is approximately 5 .ANG. to
9 .ANG. per turn of the helix, or approximately 6 .ANG. to 8 .ANG.
per turn of the helix. Where the macrocycle-forming linker spans
approximately 1 turn of a helix, the length is equal to
approximately 5 carbon-carbon bonds to 13 carbon-carbon bonds,
approximately 7 carbon-carbon bonds to 11 carbon-carbon bonds, or
approximately 9 carbon-carbon bonds. Where the macrocycle-forming
linker spans approximately 2 turns of a helix, the length is equal
to approximately 8 carbon-carbon bonds to 16 carbon-carbon bonds,
approximately 10 carbon-carbon bonds to 14 carbon-carbon bonds, or
approximately 12 carbon-carbon bonds. Where the macrocycle-forming
linker spans approximately 3 turns of a helix, the length is equal
to approximately 14 carbon-carbon bonds to 22 carbon-carbon bonds,
approximately 16 carbon-carbon bonds to 20 carbon-carbon bonds, or
approximately 18 carbon-carbon bonds. Where the macrocycle-forming
linker spans approximately 4 turns of a helix, the length is equal
to approximately 20 carbon-carbon bonds to 28 carbon-carbon bonds,
approximately 22 carbon-carbon bonds to 26 carbon-carbon bonds, or
approximately 24 carbon-carbon bonds. Where the macrocycle-forming
linker spans approximately 5 turns of a helix, the length is equal
to approximately 26 carbon-carbon bonds to 34 carbon-carbon bonds,
approximately 28 carbon-carbon bonds to 32 carbon-carbon bonds, or
approximately 30 carbon-carbon bonds. Where the macrocycle-forming
linker spans approximately 1 turn of a helix, the linkage contains
approximately 4 atoms to 12 atoms, approximately 6 atoms to 10
atoms, or approximately 8 atoms. Where the macrocycle-forming
linker spans approximately 2 turns of the helix, the linkage
contains approximately 7 atoms to 15 atoms, approximately 9 atoms
to 13 atoms, or approximately 11 atoms. Where the
macrocycle-forming linker spans approximately 3 turns of the helix,
the linkage contains approximately 13 atoms to 21 atoms,
approximately 15 atoms to 19 atoms, or approximately 17 atoms.
Where the macrocycle-forming linker spans approximately 4 turns of
the helix, the linkage contains approximately 19 atoms to 27 atoms,
approximately 21 atoms to 25 atoms, or approximately 23 atoms.
Where the macrocycle-forming linker spans approximately 5 turns of
the helix, the linkage contains approximately 25 atoms to 33 atoms,
approximately 27 atoms to 31 atoms, or approximately 29 atoms.
Where the macrocycle-forming linker spans approximately 1 turn of
the helix, the resulting macrocycle forms a ring containing
approximately 17 members to 25 members, approximately 19 members to
23 members, or approximately 21 members. Where the
macrocycle-forming linker spans approximately 2 turns of the helix,
the resulting macrocycle forms a ring containing approximately 29
members to 37 members, approximately 31 members to 35 members, or
approximately 33 members. Where the macrocycle-forming linker spans
approximately 3 turns of the helix, the resulting macrocycle forms
a ring containing approximately 44 members to 52 members,
approximately 46 members to 50 members, or approximately 48
members. Where the macrocycle-forming linker spans approximately 4
turns of the helix, the resulting macrocycle forms a ring
containing approximately 59 members to 67 members, approximately 61
members to 65 members, or approximately 63 members. Where the
macrocycle-forming linker spans approximately 5 turns of the helix,
the resulting macrocycle forms a ring containing approximately 74
members to 82 members, approximately 76 members to 80 members, or
approximately 78 members.
[0176] In other embodiments, the invention provides peptidomimetic
macrocycles of Formula (IV) or (IVa):
##STR00028##
[0177] wherein:
[0178] each A, C, D, and E is independently a natural or
non-natural amino acid;
[0179] B is a natural or non-natural amino acid, amino acid
analog,
##STR00029##
[--NH-L.sub.3-CO--], [--NH-L.sub.3-SO.sub.2--], or
[--NH-L.sub.3-];
[0180] R.sub.1 and R.sub.2 are independently --H, alkyl, alkenyl,
alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo-, or part
of a cyclic structure with an E residue;
[0181] R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with
R.sub.5;
[0182] L is a macrocycle-forming linker of the formula
-L.sub.1-L.sub.2-;
[0183] L.sub.1 and L.sub.2 are independently alkylene, alkenylene,
alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene,
cycloarylene, heterocycloarylene, or
[--R.sub.4--K--R.sub.4--].sub.n, each being optionally substituted
with R.sub.5;
[0184] each R.sub.4 is alkylene, alkenylene, alkynylene,
heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or
heteroarylene;
[0185] each K is O, S, SO, SO.sub.2, CO, CO.sub.2, or
CONR.sub.3;
[0186] each R.sub.5 is independently halogen, alkyl, --OR.sub.6,
--N(R.sub.6).sub.2, --SR.sub.6, --SOR.sub.6, --SO.sub.2R.sub.6,
--CO.sub.2R.sub.6, a fluorescent moiety, a radioisotope or a
therapeutic agent;
[0187] each R.sub.6 is independently --H, alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety,
a radioisotope or a therapeutic agent;
[0188] R.sub.7 is --H, alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl,
cycloaryl, or heterocycloaryl, optionally substituted with
R.sub.5;
[0189] v and w are independently integers from 1-1000;
[0190] u, x, y and z are independently integers from 0-10; and
[0191] n is an integer from 1-5.
[0192] In one example, at least one of R.sub.1 and R.sub.2 is
alkyl, unsubstituted or substituted with halo-. In another example,
both
[0193] R.sub.1 and R.sub.2 are independently alkyl, unsubstituted
or substituted with halo-. In some embodiments, at least one of
R.sub.1 and R.sub.2 is methyl. In other embodiments, R.sub.1 and
R.sub.2 are methyl.
[0194] In some embodiments of the invention, x+y+z is at least 1.
In other embodiments of the invention, x+y+z is at least 2. In
other embodiments of the invention, x+y+z is 3, 4, 5, 6, 7, 8, 9 or
10. Each occurrence of A, B, C, D or E in a macrocycle or
macrocycle precursor of the invention is independently selected.
For example, a sequence represented by the formula [A].sub.x, when
x is 3, encompasses embodiments where the amino acids are not
identical, e.g. Gln-Asp-Ala as well as embodiments where the amino
acids are identical, e.g. Gln-Gln-Gln. This applies for any value
of x, y, or z in the indicated ranges.
[0195] In some embodiments, the peptidomimetic macrocycle of the
invention comprises a secondary structure which is a helix and R is
--H, allowing intrahelical hydrogen bonding. In some embodiments,
at least one of A, B, C, D or E is an .alpha.,.alpha.-disubstituted
amino acid. In one example, B is an .alpha.,.alpha.-disubstituted
amino acid. For instance, at least one of A, B, C, D or E is
2-aminoisobutyric acid. In other embodiments, at least one of A, B,
C, D or E is
##STR00030##
[0196] In other embodiments, the length of the macrocycle-forming
linker L as measured from a first C.alpha. to a second C.alpha. is
selected to stabilize a desired secondary peptide structure, such
as a helix (including a 3.sub.10 helix or .alpha.-helix) formed by
residues of the peptidomimetic macrocycle including, but not
necessarily limited to, those between the first C.alpha. to a
second C.alpha..
[0197] Exemplary embodiments of the macrocycle-forming linker
-L.sub.1-L.sub.2- are shown below.
##STR00031##
Preparation of Peptidomimetic Macrocycles
[0198] Peptidomimetic macrocycles of the invention may be prepared
by any of a variety of methods known in the art. For example, any
of the residues indicated by "X" in Table 1 may be substituted with
a residue capable of forming a crosslinker with a second residue in
the same molecule or a precursor of such a residue.
[0199] Various methods to effect formation of peptidomimetic
macrocycles are known in the art. For example, the preparation of
peptidomimetic macrocycles of Formula I is described in
Schafmeister et al., J. Am. Chem. Soc. 122:5891-5892 (2000);
Schafmeister & Verdine, J. Am. Chem. Soc. 122:5891 (2005);
Walensky et al., Science 305:1466-1470 (2004); and U.S. Pat. No.
7,192,713. The .alpha.,.alpha.-disubstituted amino acids and amino
acid precursors disclosed in the cited references may be employed
in synthesis of the peptidomimetic macrocycle precursor
polypeptides. For example, the "S5-olefin amino acid" is
(S)-.alpha.-(2'-pentenyl) alanine and the "R8 olefin amino acid" is
(R)-.alpha.-(2'-octenyl) alanine. Following incorporation of such
amino acids into precursor polypeptides, the terminal olefins are
reacted with a metathesis catalyst, leading to the formation of the
peptidomimetic macrocycle.
[0200] In other embodiments, the peptidomimetic macrocyles of the
invention are of Formula IV or IVa. Methods for the preparation of
such macrocycles are described, for example, in U.S. Pat. No.
7,202,332.
[0201] In some embodiments, the synthesis of these peptidomimetic
macrocycles involves a multi-step process that features the
synthesis of a peptidomimetic precursor containing an azide moiety
and an alkyne moiety; followed by contacting the peptidomimetic
precursor with a macrocyclization reagent to generate a
triazole-linked peptidomimetic macrocycle. Such a process is
described, for example, in U.S. application Ser. No. 12/037,041,
filed on Feb. 25, 2008. Macrocycles or macrocycle precursors are
synthesized, for example, by solution phase or solid-phase methods,
and can contain both naturally-occurring and
non-naturally-occurring amino acids. See, for example, Hunt, "The
Non-Protein Amino Acids" in Chemistry and Biochemistry of the Amino
Acids, edited by G. C. Barrett, Chapman and Hall, 1985.
[0202] In some embodiments, an azide is linked to the
.alpha.-carbon of a residue and an alkyne is attached to the
.alpha.-carbon of another residue. In some embodiments, the azide
moieties are azido-analogs of amino acids L-lysine, D-lysine,
alpha-methyl-L-lysine, alpha-methyl-D-lysine, L-omithine,
D-ornithine, alpha-methyl-L-omithine or alpha-methyl-D-ornithine.
In another embodiment, the alkyne moiety is L-propargylglycine. In
yet other embodiments, the alkyne moiety is an amino acid selected
from the group consisting of L-propargylglycine,
D-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid,
(R)-2-amino-2-methyl-4-pentynoic acid,
(S)-2-amino-2-methyl-5-hexynoic acid,
(R)-2-amino-2-methyl-5-hexynoic acid,
(S)-2-amino-2-methyl-6-heptynoic acid,
(R)-2-amino-2-methyl-6-heptynoic acid,
(S)-2-amino-2-methyl-7-octynoic acid,
(R)-2-amino-2-methyl-7-octynoic acid,
(S)-2-amino-2-methyl-8-nonynoic acid and
(R)-2-amino-2-methyl-8-nonynoic acid.
[0203] In some embodiments, the invention provides a method for
synthesizing a peptidomimetic macrocycle, the method comprising the
steps of contacting a peptidomimetic precursor of Formula V or
Formula VI:
##STR00032##
[0204] with a macrocyclization reagent;
[0205] wherein v, w, x, y, z, A, B, C, D, E, R.sub.1, R.sub.2,
R.sub.7, R.sub.8, L.sub.1 and L.sub.2 are as defined for Formula
(II); R.sub.12 is --H when the macrocyclization reagent is a Cu
reagent and R.sub.12 is --H or alkyl when the macrocyclization
reagent is a Ru reagent; and further wherein said contacting step
results in a covalent linkage being formed between the alkyne and
azide moiety in Formula III or Formula IV. For example, R.sub.12
may be methyl when the macrocyclization reagent is a Ru
reagent.
[0206] In the peptidomimetic macrocycles of the invention, at least
one of R.sub.1 and R.sub.2 is alkyl, alkenyl, alkynyl, arylalkyl,
cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl,
unsubstituted or substituted with halo-. In some embodiments, both
R.sub.1 and R.sub.2 are independently alkyl, alkenyl, alkynyl,
arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or
heterocycloalkyl, unsubstituted or substituted with halo-. In some
embodiments, at least one of A, B, C, D or E is an
.alpha.,.alpha.-disubstituted amino acid. In one example, B is an
.alpha.,.alpha.-disubstituted amino acid. For instance, at least
one of A, B, C, D or E is 2-aminoisobutyric acid.
[0207] For example, at least one of R.sub.1 and R.sub.2 is alkyl,
unsubstituted or substituted with halo-. In another example, both
R.sub.1 and R.sub.2 are independently alkyl, unsubstituted or
substituted with halo-. In some embodiments, at least one of
R.sub.1 and R.sub.2 is methyl. In other embodiments, R.sub.1 and
R.sub.2 are methyl. The macrocyclization reagent may be a Cu
reagent or a Ru reagent.
[0208] In some embodiments, the peptidomimetic precursor is
purified prior to the contacting step. In other embodiments, the
peptidomimetic macrocycle is purified after the contacting step. In
still other embodiments, the peptidomimetic macrocycle is refolded
after the contacting step. The method may be performed in solution,
or, alternatively, the method may be performed on a solid
support.
[0209] Also envisioned herein is performing the method of the
invention in the presence of a target macromolecule that binds to
the peptidomimetic precursor or peptidomimetic macrocycle under
conditions that favor said binding. In some embodiments, the method
is performed in the presence of a target macromolecule that binds
preferentially to the peptidomimetic precursor or peptidomimetic
macrocycle under conditions that favor said binding. The method may
also be applied to synthesize a library of peptidomimetic
macrocycles.
[0210] In some embodiments, the alkyne moiety of the peptidomimetic
precursor of Formula V or Formula VI is a sidechain of an amino
acid selected from the group consisting of L-propargylglycine,
D-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid,
(R)-2-amino-2-methyl-4-pentynoic acid,
(S)-2-amino-2-methyl-5-hexynoic acid,
(R)-2-amino-2-methyl-5-hexynoic acid,
(S)-2-amino-2-methyl-6-heptynoic acid,
(R)-2-amino-2-methyl-6-heptynoic acid,
(S)-2-amino-2-methyl-7-octynoic acid,
(R)-2-amino-2-methyl-7-octynoic acid,
(S)-2-amino-2-methyl-8-nonynoic acid, and
(R)-2-amino-2-methyl-8-nonynoic acid. In other embodiments, the
azide moiety of the peptidomimetic precursor of Formula V or
Formula VI is a sidechain of an amino acid selected from the group
consisting of .epsilon.-azido-L-lysine, .epsilon.-azido-D-lysine,
.epsilon.-azido-.alpha.-methyl-L-lysine,
.epsilon.-azido-.alpha.-methyl-D-lysine,
.delta.-azido-.alpha.-methyl-L-omithine, and
.delta.-azido-.alpha.-methyl-D-ornithine.
[0211] In some embodiments, x+y+z is 2, and and A, B and C are
independently natural or non-natural amino acids. In other
embodiments, x+y+z is 3 or 6, and and A, B and C are independently
natural or non-natural amino acids.
[0212] In some embodiments, the contacting step is performed in a
solvent selected from the group consisting of protic solvent,
aqueous solvent, organic solvent, and mixtures thereof. For
example, the solvent may be chosen from the group consisting of
H.sub.2O, THF, THF/H.sub.2O, tBuOH/H.sub.2O, DMF, DIPEA, CH.sub.3CN
or CH.sub.2Cl.sub.2, ClCH.sub.2CH.sub.2Cl or a mixture thereof. The
solvent may be a solvent which favors helix formation.
[0213] Alternative but equivalent protecting groups, leaving groups
or reagents are substituted, and certain of the synthetic steps are
performed in alternative sequences or orders to produce the desired
compounds. Synthetic chemistry transformations and protecting group
methodologies (protection and deprotection) useful in synthesizing
the compounds described herein include, for example, those such as
described in Larock, Comprehensive Organic Transformations, VCH
Publishers (1989); Greene and Wuts, Protective Groups in Organic
Synthesis, 2d. Ed., John Wiley and Sons (1991); Fieser and Fieser,
Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and
Sons (1994); and Paquette, ed., Encyclopedia of Reagents for
Organic Synthesis, John Wiley and Sons (1995), and subsequent
editions thereof.
[0214] In some embodiments, peptidomimetic macrocycles of the
invention have the structure:
##STR00033##
[0215] The influenza PB1 peptidomimetic macrocycles shown above are
also identified as SP-8, SP-16, SP-13 and SP-41, respectively. In
other embodiments, the peptidomimetic macrocycle of the invention
has the structure:
##STR00034##
[0216] Preparation of Peptidomimetic Macrocycles.
[0217] The peptidomimetic macrocycles of the invention are made,
for example, by chemical synthesis methods, such as described in
Fields et al., Chapter 3 in Synthetic Peptides: A User's Guide, ed.
Grant, W. H. Freeman & Co., New York, N.Y., 1992, p. 77. Hence,
for example, peptides are synthesized using the automated
Merrifield techniques of solid phase synthesis with the amine
protected by either tBoc or Fmoc chemistry using side chain
protected amino acids on, for example, an automated peptide
synthesizer (e.g., Applied Biosystems (Foster City, Calif.), Model
430A, 431, or 433).
[0218] One manner of producing the peptidomimetic precursors and
peptidomimetic macrocycles described herein uses solid phase
peptide synthesis (SPPS). The C-terminal amino acid is attached to
a cross-linked polystyrene resin via an acid labile bond with a
linker molecule. This resin is insoluble in the solvents used for
synthesis, making it relatively simple and fast to wash away excess
reagents and by-products. The N-terminus is protected with the Fmoc
group, which is stable in acid, but removable by base. Side chain
functional groups are protected as necessary with base stable, acid
labile groups.
[0219] Longer peptidomimetic precursors are produced, for example,
by conjoining individual synthetic peptides using native chemical
ligation. Alternatively, the longer synthetic peptides are
biosynthesized by well known recombinant DNA and protein expression
techniques. Such techniques are provided in well-known standard
manuals with detailed protocols. To construct a gene encoding a
peptidomimetic precursor of this invention, the amino acid sequence
is reverse translated to obtain a nucleic acid sequence encoding
the amino acid sequence, preferably with codons that are optimum
for the organism in which the gene is to be expressed. Next, a
synthetic gene is made, typically by synthesizing oligonucleotides
which encode the peptide and any regulatory elements, if necessary.
The synthetic gene is inserted in a suitable cloning vector and
transfected into a host cell. The peptide is then expressed under
suitable conditions appropriate for the selected expression system
and host. The peptide is purified and characterized by standard
methods.
[0220] The peptidomimetic precursors are made, for example, in a
high-throughput, combinatorial fashion using, for example, a
high-throughput polychannel combinatorial synthesizer (e.g.,
Thuramed TETRAS multichannel peptide synthesizer from CreoSalus,
Louisville, Ky. or Model Apex 396 multichannel peptide synthesizer
from AAPPTEC, Inc., Louisville, Ky.).
[0221] The following synthetic schemes are provided solely to
illustrate the present invention and are not intended to limit the
scope of the invention, as described herein. To simplify the
drawings, the illustrative schemes depict azido amino acid analogs
.epsilon.-azido-.alpha.-methyl-L-lysine and
.epsilon.-azido-.alpha.-methyl-D-lysine, and alkyne amino acid
analogs L-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid,
and (S)-2-amino-2-methyl-6-heptynoic acid. Thus, in the following
synthetic schemes, each R.sub.1, R.sub.2, R.sub.7 and R.sub.8 is
--H; each L.sub.1 is --(CH.sub.2).sub.4--; and each L.sub.2 is
--(CH.sub.2)--. However, as noted throughout the detailed
description above, many other amino acid analogs can be employed in
which R.sub.1, R.sub.2, R.sub.7, R.sub.8, L.sub.1 and L.sub.2 can
be independently selected from the various structures disclosed
herein.
##STR00035## ##STR00036## ##STR00037##
[0222] Synthetic Scheme 1 describes the preparation of several
compounds of the invention. Ni(II) complexes of Schiff bases
derived from the chiral auxiliary
(S)-2-[N--(N'-benzylprolyl)amino]benzophenone (BPB) and amino acids
such as glycine or alanine are prepared as described in Belokon et
al. (1998), Tetrahedron Asymm. 9:4249-4252. The resulting complexes
are subsequently reacted with alkylating reagents comprising an
azido or alkynyl moiety to yield enantiomerically enriched
compounds of the invention. If desired, the resulting compounds can
be protected for use in peptide synthesis.
##STR00038##
[0223] In the general method for the synthesis of peptidomimetic
macrocycles shown in Synthetic Scheme 2, the peptidomimetic
precursor contains an azide moiety and an alkyne moiety and is
synthesized by solution-phase or solid-phase peptide synthesis
(SPPS) using the commercially available amino acid
N-.alpha.-Fmoc-L-propargylglycine and the N-.alpha.-Fmoc-protected
forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid,
(S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic
acid, N-methyl-.epsilon.-azido-L-lysine, and
N-methyl-.epsilon.-azido-D-lysine. The peptidomimetic precursor is
then deprotected and cleaved from the solid-phase resin by standard
conditions (e.g., strong acid such as 95% TFA). The peptidomimetic
precursor is reacted as a crude mixture or is purified prior to
reaction with a macrocyclization reagent such as a Cu(I) in organic
or aqueous solutions (Rostovtsev et al. (2002), Angew. Chem. Int.
Ed. 41:2596-2599; Tornoe et al. (2002), J. Org. Chem. 67:3057-3064;
Deiters et al. (2003), J. Am. Chem. Soc. 125:11782-11783; Punna et
al. (2005), Angew. Chem. Int. Ed. 44:2215-2220). In one embodiment,
the triazole forming reaction is performed under conditions that
favor helix formation. In one embodiment, the macrocyclization step
is performed in a solvent chosen from the group consisting of
H.sub.2O, THF, CH.sub.3CN, DMF, DIPEA, tBuOH or a mixture thereof.
In another embodiment, the macrocyclization step is performed in
DMF. In some embodiments, the macrocyclization step is performed in
a buffered aqueous or partially aqueous solvent.
##STR00039##
[0224] In the general method for the synthesis of peptidomimetic
macrocycles shown in Synthetic Scheme 3, the peptidomimetic
precursor contains an azide moiety and an alkyne moiety and is
synthesized by solid-phase peptide synthesis (SPPS) using the
commercially available amino acid N-.alpha.-Fmoc-L-propargylglycine
and the N-.alpha.-Fmoc-protected forms of the amino acids
(S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic
acid, (S)-2-amino-2-methyl-6-heptynoic acid,
N-methyl-.epsilon.-azido-L-lysine, and
N-methyl-.epsilon.-azido-D-lysine. The peptidomimetic precursor is
reacted with a macrocyclization reagent such as a Cu(I) reagent on
the resin as a crude mixture (Rostovtsev et al. (2002), Angew.
Chem. Int. Ed. 41:2596-2599; Tornoe et al. (2002), J. Org. Chem.
67:3057-3064; Deiters et al. (2003), J. Am. Chem. Soc.
125:11782-11783; Punna et al. (2005), Angew. Chem. Int. Ed.
44:2215-2220). The resultant triazole-containing peptidomimetic
macrocycle is then deprotected and cleaved from the solid-phase
resin by standard conditions (e.g., strong acid such as 95% TFA).
In some embodiments, the macrocyclization step is performed in a
solvent chosen from the group consisting of CH.sub.2Cl.sub.2,
CICH.sub.2CH.sub.2Cl, DMF, THF, NMP, DIPEA, 2,6-lutidine, pyridine,
DMSO, H.sub.2O or a mixture thereof. In some embodiments, the
macrocyclization step is performed in a buffered aqueous or
partially aqueous solvent.
##STR00040##
[0225] In the general method for the synthesis of peptidomimetic
macrocycles shown in Synthetic Scheme 4, the peptidomimetic
precursor contains an azide moiety and an alkyne moiety and is
synthesized by solution-phase or solid-phase peptide synthesis
(SPPS) using the commercially available amino acid
N-.alpha.-Fmoc-L-propargylglycine and the N-.alpha.-Fmoc-protected
forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid,
(S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic
acid, N-methyl-.epsilon.-azido-L-lysine, and
N-methyl-.epsilon.-azido-D-lysine. The peptidomimetic precursor is
then deprotected and cleaved from the solid-phase resin by standard
conditions (e.g., strong acid such as 95% TFA). The peptidomimetic
precursor is reacted as a crude mixture or is purified prior to
reaction with a macrocyclization reagent such as a Ru(II) reagents,
for example Cp*RuCl(PPh.sub.3).sub.2 or [Cp*RuCl].sub.4 (Rasmussen
et al. (2007), Org. Lett. 9:5337-5339; Zhang et al. (2005), J. Am.
Chem. Soc. 127:15998-15999). In some embodiments, the
macrocyclization step is performed in a solvent chosen from the
group consisting of DMF, CH.sub.3CN and THF.
##STR00041##
[0226] In the general method for the synthesis of peptidomimetic
macrocycles shown in Synthetic Scheme 5, the peptidomimetic
precursor contains an azide moiety and an alkyne moiety and is
synthesized by solid-phase peptide synthesis (SPPS) using the
commercially available amino acidN-.alpha.-Fmoc-L-propargylglycine
and the N-.alpha.-Fmoc-protected forms of the amino acids
(S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic
acid, (S)-2-amino-2-methyl-6-heptynoic acid,
N-methyl-.epsilon.-azido-L-lysine, and
N-methyl-.epsilon.-azido-D-lysine. The peptidomimetic precursor is
reacted with a macrocyclization reagent such as a Ru(II) reagent on
the resin as a crude mixture. For example, the reagent can be
Cp*RuCl(PPh.sub.3).sub.2 or [Cp*RuCl].sub.4 (Rasmussen et al.
(2007), Org. Lett. 9:5337-5339; Zhang et al. (2005), J. Am. Chem.
Soc. 127:15998-15999). In some embodiments, the macrocyclization
step is performed in a solvent chosen from the group consisting of
CH.sub.2Cl.sub.2, ClCH.sub.2CH.sub.2Cl, CH.sub.3CN, DMF, and
THF.
[0227] The present invention contemplates the use of
non-naturally-occurring amino acids and amino acid analogs in the
synthesis of the peptidomimetic macrocycles described herein. Any
amino acid or amino acid analog amenable to the synthetic methods
employed for the synthesis of stable triazole containing
peptidomimetic macrocycles can be used in the present invention.
For example, L-propargylglycine is contemplated as a useful amino
acid in the present invention. However, other alkyne-containing
amino acids that contain a different amino acid side chain are also
useful in the invention. For example, L-propargylglycine contains
one methylene unit between the .alpha.-carbon of the amino acid and
the alkyne of the amino acid side chain. The invention also
contemplates the use of amino acids with multiple methylene units
between the .alpha.-carbon and the alkyne. Also, the azido-analogs
of amino acids L-lysine, D-lysine, alpha-methyl-L-lysine, and
alpha-methyl-D-lysine are contemplated as useful amino acids in the
present invention. However, other terminal azide amino acids that
contain a different amino acid side chain are also useful in the
invention. For example, the azido-analog of L-lysine contains four
methylene units between the .alpha.-carbon of the amino acid and
the terminal azide of the amino acid side chain. The invention also
contemplates the use of amino acids with fewer than or greater than
four methylene units between the .alpha.-carbon and the terminal
azide. Table 2 shows some amino acids useful in the preparation of
peptidomimetic macrocycles of the invention.
TABLE-US-00005 TABLE 2 ##STR00042## N-.alpha.-Fmoc-L-propargyl
glycine ##STR00043## N-.alpha.-Fmoc-D-propargyl glycine
##STR00044## N-.alpha.-Fmoc-(S)-2-amino-2-methyl-4-pentynoic acid
##STR00045## N-.alpha.-Fmoc-(R)-2-amino-2-methyl-4-pentynoic acid
##STR00046## N-.alpha.-Fmoc-.epsilon.-azido-L-lysine ##STR00047##
N-.alpha.-Fmoc-.epsilon.-azido-D-lysine ##STR00048##
N-.alpha.-Fmoc-(S)-2-amino-2-methyl-5-hexynoic acid ##STR00049##
N-.alpha.-Fmoc-(R)-2-amino-2-methyl-5-hexynoic acid ##STR00050##
N-.alpha.-Fmoc-.epsilon.-azido-.alpha.-methyl-L-lysine ##STR00051##
N-.alpha.-Fmoc-.epsilon.-azido-.alpha.-methyl-D-lysine ##STR00052##
N-.alpha.-Fmoc-(S)-2-amino-2-methyl-6-heptynoic acid ##STR00053##
N-.alpha.-Fmoc-(R)-2-amino-2-methyl-6-heptynoic acid ##STR00054##
N-.alpha.-Fmoc-(S)-2-amino-2-methyl-7-octynoic acid ##STR00055##
N-.alpha.-Fmoc-(R)-2-amino-2-methyl-7-octynoic acid ##STR00056##
N-.alpha.-Fmoc-.delta.-azido-L-ornithine ##STR00057##
N-.alpha.-Fmoc-.delta.-azido-D-ornithine ##STR00058##
N-.alpha.-Fmoc-(S)-2-amino-2-methyl-8-nonynoic acid ##STR00059##
N-.alpha.-Fmoc-(R)-2-amino-2-methyl-8-nonynoic acid ##STR00060##
N-.alpha.-Fmoc-.epsilon.-azido-.alpha.-methyl-L-ornithine
##STR00061##
N-.alpha.-Fmoc-.epsilon.-azido-.alpha.-methyl-D-ornithine
[0228] Table 2 shows exemplary amino acids useful in the
preparation of peptidomimetic macrocycles of the invention.
[0229] In some embodiments the amino acids and amino acid analogs
are of the D-configuration. In other embodiments they are of the
L-configuration. In some embodiments, some of the amino acids and
amino acid analogs contained in the peptidomimetic are of the
D-configuration while some of the amino acids and amino acid
analogs are of the L-configuration. In some embodiments the amino
acid analogs are .alpha.,.alpha.-disubstituted, such as
.alpha.-methyl-L-propargylglycine,
.alpha.-methyl-D-propargylglycine,
.epsilon.-azido-alpha-methyl-L-lysine, and
.epsilon.-azido-alpha-methyl-D-lysine.
[0230] In some embodiments the amino acid analogs are N-alkylated,
e.g., N-methyl-L-propargylglycine, N-methyl-D-propargylglycine,
N-methyl-.epsilon.-azido-L-lysine, and
N-methyl-.epsilon.-azido-D-lysine.
[0231] In some embodiments, the --NH moiety of the amino acid is
protected using a protecting group, including without limitation
-Fmoc and -Boc. In other embodiments, the amino acid is not
protected prior to synthesis of the peptidomimetic macrocycle.
[0232] In other embodiments, peptidomimetic macrocycles of Formula
III are synthesized. The preparation of such macrocycles is
described, for example, in U.S. application Ser. No. 11/957,325,
filed on Dec. 17, 2007. The following synthetic schemes describe
the preparation of such compounds. To simplify the drawings, the
illustrative schemes depict amino acid analogs derived from L- or
D-cysteine, in which L.sub.1 and L.sub.3 are both --(CH.sub.2)--.
However, as noted throughout the detailed description above, many
other amino acid analogs can be employed in which L.sub.1 and
L.sub.3 can be independently selected from the various structures
disclosed herein. The symbols "[AA].sub.m", "[AA].sub.n",
"[AA].sub.o" represent a sequence of amide bond-linked moieties
such as natural or unnatural amino acids. As described previously,
each occurrence of "AA" is independent of any other occurrence of
"AA", and a formula such as "[AA].sub.m" encompasses, for example,
sequences of non-identical amino acids as well as sequences of
identical amino acids.
##STR00062##
[0233] In Scheme 6, the peptidomimetic precursor contains two --SH
moieties and is synthesized by solid-phase peptide synthesis (SPPS)
using commercially available N-.alpha.-Fmoc amino acids such as
N-.alpha.-Fmoc-S-trityl-L-cysteine or
N-.alpha.-Fmoc-S-trityl-D-cysteine. Alpha-methylated versions of
D-cysteine or L-cysteine are generated by known methods (Seebach et
al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708-2748, and
references therein) and then converted to the appropriately
protected N-.alpha.-Fmoc-S-trityl monomers by known methods
("Bioorganic Chemistry: Peptides and Proteins", Oxford University
Press, New York: 1998, the entire contents of which are
incorporated herein by reference). The precursor peptidomimetic is
then deprotected and cleaved from the solid-phase resin by standard
conditions (e.g., strong acid such as 95% TFA). The precursor
peptidomimetic is reacted as a crude mixture or is purified prior
to reaction with X-L.sub.2-Y in organic or aqueous solutions. In
some embodiments the alkylation reaction is performed under dilute
conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to
avoid polymerization. In some embodiments, the alkylation reaction
is performed in organic solutions such as liquid NH.sub.3 (Mosberg
et al. (1985), J. Am.Chem. Soc. 107:2986-2987; Szewezuk et al.
(1992), Int. J. Peptide Protein Res. 40:233-242), NH.sub.3/McOH, or
NH.sub.3/DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). In
other embodiments, the alkylation is performed in an aqueous
solution such as 6M guanidinium HCL, pH 8 (Brunel ct al. (2005),
Chem. Commun. (20):2552-2554). In other embodiments, the solvent
used for the alkylation reaction is DMF or dichloroethane.
##STR00063##
[0234] In Scheme 7, the precursor peptidomimetic contains two or
more --SH moieties, of which two are specially protected to allow
their selective deprotection and subsequent alkylation for
macrocycle formation. The precursor peptidomimetic is synthesized
by solid-phase peptide synthesis (SPPS) using commercially
available N-.alpha.-Fmoc amino acids such as
N-.alpha.-Fmoc-S-p-methoxytrityl-L-cysteine or
N-.alpha.-Fmoc-S-p-methoxytrityl-D-cysteine. Alpha-methylated
versions of D-cysteine or L-cysteine are generated by known methods
(Seebach et al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708-2748,
and references therein) and then converted to the appropriately
protected N-.alpha.-Fmoc-S-p-methoxytrityl monomers by known
methods (Bioorganic Chemistry: Peptides and Proteins, Oxford
University Press, New York: 1998, the entire contents of which are
incorporated herein by reference). The Mmt protecting groups of the
peptidomimetic precursor are then selectively cleaved by standard
conditions (e.g., mild acid such as 1% TFA in DCM). The precursor
peptidomimetic is then reacted on the resin with X-L.sub.2-Y in an
organic solution. For example, the reaction takes place in the
presence of a hindered base such as diisopropylethylamine. In some
embodiments, the alkylation reaction is performed in organic
solutions such as liquid NH.sub.3 (Mosberg et al. (1985), J.
Am.Chem. Soc. 107:2986-2987; Szewezuk et al. (1992), Int. J.
Peptide Protein Res. 40:233-242), NH.sub.3/MeOH or NH.sub.3/DMF (Or
et al. (1991), J. Org. Chem. 56:3146-3149). In other embodiments,
the alkylation reaction is performed in DMF or dichloroethane. The
peptidomimetic macrocycle is then deprotected and cleaved from the
solid-phase resin by standard conditions (e.g., strong acid such as
95% TFA).
##STR00064##
[0235] In Scheme 8, the peptidomimetic precursor contains two or
more --SH moieties, of which two are specially protected to allow
their selective deprotection and subsequent alkylation for
macrocycle formation. The peptidomimetic precursor is synthesized
by solid-phase peptide synthesis (SPPS) using commercially
available N-.alpha.-Fmoc amino acids such as
N-.alpha.-Fmoc-S-p-methoxytrityl-L-cysteine,
N-.alpha.-Fmoc-S-p-methoxytrityl-D-cysteine,
N-.alpha.-Fmoc-S-S-t-butyl-L-cysteine, and
N-.alpha.-Fmoc-S-S-t-butyl-D-cysteine. Alpha-methylated versions of
D-cysteine or L-cysteine are generated by known methods (Seebach et
al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708-2748, and
references therein) and then converted to the appropriately
protected N-.alpha.-Fmoc-S-p-methoxytrityl or
N-.alpha.-Fmoc-S-S-t-butyl monomers by known methods (Bioorganic
Chemistry: Peptides and Proteins, Oxford University Press, New
York: 1998, the entire contents of which are incorporated herein by
reference). The S-S-tButyl protecting group of the peptidomimetic
precursor is selectively cleaved by known conditions (e.g., 20%
2-mercaptoethanol in DMF, reference: Galande et al. (2005), J.
Comb. Chem. 7:174-177). The precursor peptidomimetic is then
reacted on the resin with a molar excess of X-L.sub.2-Y in an
organic solution. For example, the reaction takes place in the
presence of a hindered base such as diisopropylethylamine. The Mmt
protecting group of the peptidomimetic precursor is then
selectively cleaved by standard conditions (e.g., mild acid such as
1% TFA in DCM). The peptidomimetic precursor is then cyclized on
the resin by treatment with a hindered base in organic solutions.
In some embodiments, the alkylation reaction is performed in
organic solutions such as NH.sub.3/MeOH or NH.sub.3/DMF (Or et al.
(1991), J. Org. Chem. 56:3146-3149). The peptidomimetic macrocycle
is then deprotected and cleaved from the solid-phase resin by
standard conditions (e.g., strong acid such as 95% TFA).
##STR00065##
[0236] In Scheme 9, the peptidomimetic precursor contains two
L-cysteine moieties. The peptidomimetic precursor is synthesized by
known biological expression systems in living cells or by known in
vitro, cell-free, expression methods. The precursor peptidomimetic
is reacted as a crude mixture or is purified prior to reaction with
X-L2-Y in organic or aqueous solutions. In some embodiments the
alkylation reaction is performed under dilute conditions (i.e. 0.15
mmol/L) to favor macrocyclization and to avoid polymerization. In
some embodiments, the alkylation reaction is performed in organic
solutions such as liquid NH.sub.3 (Mosberg et al. (1985), J.
Am.Chem. Soc. 107:2986-2987; Szewezuk et al. (1992), Int. J.
Peptide Protein Res. 40:233-242), NH.sub.3/MeOH, or NH.sub.3/DMF
(Or et al. (1991), J. Org. Chem. 56:3146-3149). In other
embodiments, the alkylation is performed in an aqueous solution
such as 6M guanidinium HCL, pH 8 (Brunel et al. (2005), Chem.
Commun. (20):2552-2554). In other embodiments, the alkylation is
performed in DMF or dichloroethane. In another embodiment, the
alkylation is performed in non-denaturing aqueous solutions, and in
yet another embodiment the alkylation is performed under conditions
that favor helical structure formation. In yet another embodiment,
the alkylation is performed under conditions that favor the binding
of the precursor peptidomimetic to another protein, so as to induce
the formation of the bound helical conformation during the
alkylation.
[0237] Various embodiments for X and Y are envisioned which are
suitable for reacting with thiol groups. In general, each X or Y is
independently be selected from the general category shown in Table
5. For example, X and Y are halides such as --Cl, --Br or --I. Any
of the macrocycle-forming linkers described herein may be used in
any combination with any of the sequences shown in Tables 1-4 and
also with any of the R-- substituents indicated herein.
TABLE-US-00006 TABLE 3 Examples of Reactive Groups Capable of
Reacting with Thiol Groups and Resulting Linkages X or Y Resulting
Covalent Linkage acrylamide Thioether halide (e.g. alkyl or aryl
halide) Thioether sulfonate Thioether aziridine Thioether epoxide
Thioether haloacetamide Thioether maleimide Thioether sulfonate
ester Thioether
[0238] The present invention contemplates the use of both
naturally-occurring and non-naturally-occurring amino acids and
amino acid analogs in the synthesis of the peptidomimetic
macrocycles of Formula (III). Any amino acid or amino acid analog
amenable to the synthetic methods employed for the synthesis of
stable bis-sulfhydryl containing peptidomimetic macrocycles can be
used in the present invention. For example, cysteine is
contemplated as a useful amino acid in the present invention.
However, sulfur containing amino acids other than cysteine that
contain a different amino acid side chain are also useful. For
example, cysteine contains one methylene unit between the
.alpha.-carbon of the amino acid and the terminal --SH of the amino
acid side chain. The invention also contemplates the use of amino
acids with multiple methylene units between the .alpha.-carbon and
the terminal --SH. Non-limiting examples include
.alpha.-methyl-L-homocysteine and .alpha.-methyl-D-homocysteine. In
some embodiments the amino acids and amino acid analogs are of the
D-configuration. In other embodiments they are of the
L-configuration. In some embodiments, some of the amino acids and
amino acid analogs contained in the peptidomimetic are of the
D-configuration while some of the amino acids and amino acid
analogs are of the L-configuration. In some embodiments the amino
acid analogs are .alpha.,.alpha.-disubstituted, such as
.alpha.-methyl-L-cysteine and .alpha.-methyl-D-cysteine.
[0239] The invention includes macrocycles in which
macrocycle-forming linkers are used to link two or more --SH
moieties in the peptidomimetic precursors to form the
peptidomimetic macrocycles of the invention. As described above,
the macrocycle-forming linkers impart conformational rigidity,
increased metabolic stability and/or increased cell penetrability.
Furthermore, in some embodiments, the macrocycle-forming linkages
stabilize a helical secondary structure of the peptidomimetic
macrocyles. The macrocycle-forming linkers are of the formula
X-L.sub.2-Y, wherein both X and Y are the same or different
moieties, as defined above. Both X and Y have the chemical
characteristics that allow one macrocycle-forming linker -L.sub.2-
to bis alkylate the bis-sulfhydryl containing peptidomimetic
precursor. As defined above, the linker -L.sub.2- includes
alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene,
heterocycloalkylene, cycloarylene, or heterocycloarylene, or
--R.sub.4--K--R.sub.4--, all of which can be optionally substituted
with an R.sub.5 group, as defined above. Furthermore, one to three
carbon atoms within the macrocycle-forming linkers -L.sub.2-, other
than the carbons attached to the --SH of the sulfhydryl containing
amino acid, are optionally substituted with a heteroatom such as N,
S or O.
[0240] The L.sub.2 component of the macrocycle-forming linker
X-L.sub.2-Y may be varied in length depending on, among other
things, the distance between the positions of the two amino acid
analogs used to form the peptidomimetic macrocycle. Furthermore, as
the lengths of L.sub.1 and/or L.sub.3 components of the
macrocycle-forming linker are varied, the length of L.sub.2 can
also be varied in order to create a linker of appropriate overall
length for forming a stable peptidomimetic macrocycle. For example,
if the amino acid analogs used are varied by adding an additional
methylene unit to each of L.sub.1 and L.sub.3, the length of
L.sub.2 are decreased in length by the equivalent of approximately
two methylene units to compensate for the increased lengths of
L.sub.1 and L.sub.3.
[0241] In some embodiments, L.sub.2 is an alkylene group of the
formula --(CH.sub.2).sub.n--, where n is an integer between about 1
and about 15. For example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In
other embodiments, L.sub.2 is an alkenylene group. In still other
embodiments, L.sub.2 is an aryl group.
[0242] Table 4 shows additional embodiments of X-L.sub.2-Y
groups.
TABLE-US-00007 TABLE 4 Exemplary X--L.sub.2--Y groups of the
invention. ##STR00066## ##STR00067## ##STR00068## ##STR00069##
##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074##
##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079##
##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084##
##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089##
##STR00090## ##STR00091## ##STR00092## ##STR00093## ##STR00094##
##STR00095## ##STR00096## ##STR00097## ##STR00098## ##STR00099##
##STR00100## ##STR00101## ##STR00102## ##STR00103## ##STR00104##
##STR00105## ##STR00106## ##STR00107## ##STR00108## Each X and Y in
this table, is, for example, independently Cl--, Br-- or I--.
[0243] Additional methods of forming peptidomimetic macrocycles
which are envisioned as suitable to perform the present invention
include those disclosed by Mustapa, M. Firouz Mohd et al., J. Org.
Chem (2003), 68, pp. 8193-8198; Yang, Bin et al. Bioorg Med. Chem.
Left. (2004), 14, pp. 1403-1406; U.S. Pat. No. 5,364,851; U.S. Pat.
No. 5,446,128; U.S. Pat. No. 5,824,483; U.S. Pat. No. 6,713,280;
and U.S. Pat. No. 7,202,332. Tn such embodiments, aminoacid
precursors are used containing an additional substituent R-- at the
alpha position. Such aminoacids are incorporated into the
macrocycle precursor at the desired positions, which may be at the
positions where the crosslinker is substituted or, alternatively,
elsewhere in the sequence of the macrocycle precursor. Cyclization
of the precursor is then effected according to the indicated
method.
[0244] In some embodiments, it is desirable to modify the
configuration of the resulting peptidomimetic macrocycle. For
instance, when a 3.sub.10 helical configuration is more desirable,
additional substitutions or modifications to the macrocycle can be
made to induce or bias such conformations, such as substituting
2-aminoisobutyric acid (Aib) for one or more amino acids in the
sequence of the invention. See, for example, Boal et. al., J. Am.
Chem. Soc. 2007, 129, 6986-6987. In one embodiments, the helical
macrocycle of the invention comprises at least 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, or more Aib substitutions.
Assays
[0245] The properties of the peptidomimetic macrocycles of the
invention are assayed, for example, by using the methods described
below. In some embodiments, a peptidomimetic macrocycle of the
invention has improved biological properties relative to a
corresponding polypeptide lacking the substituents described
herein.
Assay to Determine Helicity.
[0246] In solution, the secondary structure of polypeptides with
helical domains will reach a dynamic equilibrium between random
coil structures and helical structures, often expressed as a
"percent helicity". Thus, for example, unmodified helical domains
may be predominantly random coils in solution, with helical content
usually under 25%. Peptidomimetic macrocycles with optimized
linkers, on the other hand, possess, for example, a helicity that
is at least two-fold greater than that of a corresponding
uncrosslinked polypeptide. In some embodiments, macrocycles of the
invention will possess a helicity of greater than 50%. To assay the
helicity of peptidomimetic macrocyles of the invention, the
compounds are dissolved in an aqueous solution (e.g. 50 mM
potassium phosphate solution at pH 7, or distilled H.sub.2O, to
concentrations of 25-50 .mu.M). Circular dichroism (CD) spectra are
obtained on a spectropolarimeter (e.g., Jasco J-710) using standard
measurement parameters (e.g. temperature, 20.degree. C.;
wavelength, 190-260 nm; step resolution, 0.5 nm; speed, 20 nm/sec;
accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length,
0.1 cm). The helical content of each peptide is calculated by
dividing the mean residue ellipticity (e.g. [.PHI.]222 obs) by the
reported value for a model helical decapeptide (Yang et al. (1986),
Methods Enzymol. 130:208)).
Assay to Determine Melting Temperature (Tm).
[0247] A peptidomimetic macrocycle of the invention comprising a
secondary structure such as a helix exhibits, for example, a higher
melting temperature than a corresponding uncrosslinked polypeptide.
Typically peptidomimetic macrocycles of the invention exhibit Tm of
>60.degree. C. representing a highly stable structure in aqueous
solutions. To assay the effect of macrocycle formation on meltine
temperature, peptidomimetic macrocycles or unmodified peptides are
dissolved in distilled H.sub.2O (e.g. at a final concentration of
50 .mu.M) and the Tm is determined by measuring the change in
ellipticity over a temperature range (e.g. 4 to 95.degree. C.) on a
spectropolarimeter (e.g., Jasco J-710) using standard parameters
(e.g. wavelength 222 nm; step resolution, 0.5 nm; speed, 20 nm/sec;
accumulations, 10; response, 1 sec; bandwidth, 1 nm; temperature
increase rate: 1.degree. C./min; path length, 0.1 cm).
Protease Resistance Assay.
[0248] The amide bond of the peptide backbone is susceptible to
hydrolysis by proteases, thereby rendering peptidic compounds
vulnerable to rapid degradation in vivo. Peptide helix formation,
however, typically buries the amide backbone and therefore may
shield it from proteolytic cleavage. The peptidomimetic macrocycles
of the present invention may be subjected to in vitro trypsin
proteolysis to assess for any change in degradation rate compared
to a corresponding uncrosslinked polypeptide. For example, the
peptidomimetic macrocycle and a corresponding uncrosslinked
polypeptide are incubated with trypsin agarose and the reactions
quenched at various time points by centrifugation and subsequent
HPLC injection to quantitate the residual substrate by ultraviolet
absorption at 280 nm. Briefly, the peptidomimetic macrocycle and
peptidomimetic precursor (5 meg) are incubated with trypsin agarose
(Pierce) (S/E.about.125) for 0, 10, 20, 90, and 180 minutes.
Reactions are quenched by tabletop centrifugation at high speed;
remaining substrate in the isolated supernatant is quantified by
HPLC-based peak detection at 280 nm. The proteolytic reaction
displays first order kinetics and the rate constant, k, is
determined from a plot of ln[S] versus time (k=-1Xslope).
Ex Vivo Stability Assay.
[0249] Peptidomimetic macrocycles with optimized linkers possess,
for example, an ex vivo half-life that is at least two-fold greater
than that of a corresponding uncrosslinked polypeptide, and possess
an ex vivo half-life of 12 hours or more. For ex vivo serum
stability studies, a variety of assays may be used. For example, a
peptidomimetic macrocycle and a corresponding uncrosslinked
polypeptide (2 meg) are incubated with fresh mouse, rat and/or
human serum (2 mL) at 37.degree. C. for 0, 1, 2, 4, 8, and 24
hours. To determine the level of intact compound, the following
procedure may be used: The samples are extracted by transferring
100 .mu.l of sera to 2 ml centrifuge tubes followed by the addition
of 10 .mu.L of 50% formic acid and 500 .mu.L acetonitrile and
centrifugation at 14,000 RPM for 10 min at 4.+-.2.degree. C. The
supernatants are then transferred to fresh 2 ml tubes and
evaporated on Turbovap under N.sub.2<10 psi, 37.degree. C. The
samples are reconstituted in 100 .mu.L of 50:50 acetonitrile:water
and submitted to LC-MS/MS analysis.
In Vitro Binding Assays.
[0250] To assess the binding and affinity of peptidomimetic
macrocycles and peptidomimetic precursors to acceptor proteins, a
fluorescence polarization assay (FPA) is used, for example. The FPA
technique measures the molecular orientation and mobility using
polarized light and fluorescent tracer. When excited with polarized
light, fluorescent tracers (e.g., FITC) attached to molecules with
high apparent molecular weights (e.g. FITC-labeled peptides bound
to a large protein) emit higher levels of polarized fluorescence
due to their slower rates of rotation as compared to fluorescent
tracers attached to smaller molecules (e.g. FITC-labeled peptides
that are free in solution).
[0251] For example, fluoresceinated peptidomimetic macrocycles (25
nM) are incubated with the acceptor protein (25-1000 nM) in binding
buffer (140 mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room
temperature. Binding activity is measured, for example, by
fluorescence polarization on a luminescence spectrophotometer (e.g.
Perkin-Elmer LS50B). Kd values may be determined by nonlinear
regression analysis using, for example, Graphpad Prism software
(GraphPad Software, Inc., San Diego, Calif.). A peptidomimetic
macrocycle of the invention shows, in some instances, similar or
lower Kd than a corresponding uncrosslinked polypeptide.
In Vitro Displacement Assays to Characterize Antagonists of
Peptide-Protein Interactions.
[0252] To assess the binding and affinity of compounds that
antagonize the interaction between a peptide and an acceptor
protein, a fluorescence polarization assay (FPA) utilizing a
fluoresceinated peptidomimetic macrocycle derived from a
peptidomimetic precursor sequence is used, for example. The FPA
technique measures the molecular orientation and mobility using
polarized light and fluorescent tracer. When excited with polarized
light, fluorescent tracers (e.g., FITC) attached to molecules with
high apparent molecular weights (e.g. FITC-labeled peptides bound
to a large protein) emit higher levels of polarized fluorescence
due to their slower rates of rotation as compared to fluorescent
tracers attached to smaller molecules (e.g. FITC-labeled peptides
that are free in solution). A compound that antagonizes the
interaction between the fluoresceinated peptidomimetic macrocycle
and an acceptor protein will be detected in a competitive binding
FPA experiment.
[0253] For example, putative antagonist compounds (1 nM to 1 mM)
and a fluoresceinated peptidomimetic macrocycle (25 nM) are
incubated with the acceptor protein (50 nM) in binding buffer (140
mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room
temperature. Antagonist binding activity is measured, for example,
by fluorescence polarization on a luminescence spectrophotometer
(e.g. Perkin-Elmer LS50B). Kd values may be determined by nonlinear
regression analysis using, for example, Graphpad Prism software
(GraphPad Software, Inc., San Diego, Calif.).
[0254] Any class of molecule, such as small organic molecules,
peptides, oligonucleotides or proteins can be examined as putative
antagonists in this assay.
Binding Assays in Intact Cells.
[0255] It is possible to measure binding of peptides or
peptidomimetic macrocycles to their natural acceptors in intact
cells by immunoprecipitation experiments. For example, intact cells
are incubated with fluoresceinated (FITC-labeled) compounds for 4
hrs in the absence of serum, followed by serum replacement and
further incubation that ranges from 4-18 hrs. Cells are then
pelleted and incubated in lysis buffer (50 mM Tris [pH 7.6], 150 mM
NaCl, 1% CHAPS and protease inhibitor cocktail) for 10 minutes at
4.degree. C. Extracts are centrifuged at 14,000 rpm for 15 minutes
and supernatants collected and incubated with 10 .mu.l goat
anti-FITC antibody for 2 hrs, rotating at 4.degree. C. followed by
further 2 hrs incubation at 4.degree. C. with protein A/G Sepharose
(50 .mu.l of 50% bead slurry). After quick centrifugation, the
pellets are washed in lysis buffer containing increasing salt
concentration (e.g., 150, 300, 500 mM). The beads are then
re-equilibrated at 150 mM NaCl before addition of SDS-containing
sample buffer and boiling. After centrifugation, the supernatants
are optionally electrophoresed using 4%-12% gradient Bis-Tris gels
followed by transfer into Immobilon-P membranes. After blocking,
blots are optionally incubated with an antibody that detects FITC
and also with one or more antibodies that detect proteins that bind
to the peptidomimetic macrocycle.
Cellular Penetrability Assays
[0256] A peptidomimetic macrocycle is, for example, more cell
penetrable compared to a corresponding uncrosslinked macrocycle.
Peptidomimetic macrocycles with optimized linkers possess, for
example, cell penetrability that is at least two-fold greater than
a corresponding uncrosslinked macrocycle, and often 20% or more of
the applied peptidomimetic macrocycle will be observed to have
penetrated the cell after 4 hours. To measure the cell
penetrability of peptidomimetic macrocycles and corresponding
uncrosslinked macrocycle, intact cells are incubated with
fluoresceinated peptidomimetic macrocycles or corresponding
uncrosslinked macrocycle (10 .mu.M) for 4 hrs in serum free media
at 37.degree. C., washed twice with media and incubated with
trypsin (0.25%) for 10 min at 37.degree. C. The cells are washed
again and resuspended in PBS. Cellular fluorescence is analyzed,
for example, by using either a FACSCalibur flow cytometer or
Cellomics' KineticScan.RTM. HCS Reader.
In Vivo Stability Assay.
[0257] To investigate the in vivo stability of the peptidomimetic
macrocycles, the compounds are, for example, administered to mice
and/or rats by IV, IP, PO or inhalation routes at concentrations
ranging from 0.1 to 50 mg/kg and blood specimens withdrawn at 0',
5', 15', 30', 1 hr, 4 hrs, 8 hrs and 24 hours post-injection.
Levels of intact compound in 25 .mu.L of fresh scrum are then
measured by LC-MS/MS as above.
In Vitro Testing for Inhibition of Influenza Replication
[0258] This influenza antiviral evaluation assay examines the
effects of compounds at designated dose-response concentrations.
See also Noah, J. W., W. Severson, D. L. Noah, L. Rasmussen, E. L.
White, and C. B. Jonsson, Antiviral Res, 2007. 73(1): p. 50-9.
Malin Darby canine kidney (MDCK) cells are used in the assay to
test the efficacy of the compounds in preventing the cytopathic
effect (CPE) induced by influenza infection. Either Ribavirin or
Tamiflu is included in each run as a positive control compound.
Subconfluent cultures of MDCK cells are plated into 96-well plates
for the analysis of cell viability (cytotoxicity) and antiviral
activity (CPE). Drugs are added to the cells 24 hours later. At a
designated time, the CPE wells also receive 100 tissue culture
infectious doses (100 TCID.sub.50s) of titered influenza virus. 72
hours later the cell viability is determined. The effective
compound concentrations which reduce viral-induced CPE by 25%
(IC.sub.25), 50% (IC.sub.50), and 90% (IC.sub.90) are calculated by
regression analysis with semi-log curve fitting. Cell viability is
assessed using CellTiter-Glo (Promega). The toxic concentration of
drug that reduces cell numbers by 50% and 90% (TC.sub.50 and
TC.sub.90, respectively) are calculated as well. Selectivity
(therapeutic) indices (SI=TC/IC) are also calculated.
In Vivo Testing for Inhibition of Influenza Replication
[0259] In vivo testing of compounds of the invention can be
performed, including testing on mammals such as rats or ferrets.
Because ferrets (Mustela putorius furo) are naturally susceptible
to infection with human influenza A and B viruses and their disease
resembles that of human influenza, these animals have been widely
used as a model for influenza virus pathogenesis and immunity
studies. See Sidwell, R. W. and D. F. Smee, Antiviral Res,
2000.48(1): p. 1-16; and Colacino, J. M., D. C. DeLong, J. R.
Nelson, W. A. Spitzer, J. Tang, F. Victor, and C. Y. Wu, Antimicrob
Agents Chemother, 1990. 34(11): p. 2156-63. Ferrets are also the
model of choice for the study of avian influenza virus H5N1
pathogenesis in mammals. See also Zitzow, L. A., T. Rowe, T.
Morken, W. -J. Shieh, S. Zaki, and J. M. Katz, Pathogenesis of
Avian Influenza A (H5N1) Viruses in Ferrets. 2002. p. 4420-4429.
The activities of the PB1 Stapled Peptides can be compared to
Ribavirin or Oseltamivir as a positive control.
[0260] Briefly, young adult male or female ferrets (five ferrets
for each treatment group) that are serologically negative by
hemagglutination inhibition assay for currently circulating human
influenza A or B viruses are quarantined at least 4 days prior to
infection in a BSL-3+ animal holding area, where they are housed in
cages contained in bioclean portable laminar flow clean room
enclosures (Lab Products, Seaford, Del.). Prior to infection,
baseline temperatures are measured twice daily for at least 3 days.
Ferrets are anesthetized with ketamine (25 mg/kg), xylazine (2
mg/kg), and atropine (0.05 mg/kg) by the intramuscular route and
infected intranasally (i.n.) with virus/ml in phosphate-buffered
saline (PBS) delivered to the nostrils. Control animals are
mock-infected with an equivalent dilution (1:30) of noninfectious
allantoic fluid. Stapled Peptides are administered i.v. or i.p. one
hour after virus infection. Temperatures are measured twice daily
using either a rectal thermometer or a subcutaneous implantable
temperature transponder (BioMedic Data Systems, Inc., Seaford,
Del.) with pre-infection values averaged to obtain a baseline
temperature for each ferret. The change in temperature (in degrees
Celsius) is calculated at each time point for each animal. Clinical
signs of sneezing (before anesthesia), inappetence, dyspnea, and
level of activity are assessed. A scoring system is also used to
assess the activity level, and based on the daily scores for each
animal in a group a relative inactivity index will be calculated.
Rectal temperature and activity scores are used to assess the
severity of influenza infection and the ability of Stapled Peptides
to prevent flu symptoms.
Assaying Inhibition of Viral Polymerase Complex Assembly and
Activity.
[0261] The technique of Bimolecular Fluorescence Complementation
("BiFC") may be used to assay the compounds of the invention. In
this technique, N- and C-terminal fragments of fluorescent proteins
(e.g. GFP or its derivatives) are fused to interacting proteins.
The two non-functional halves of the fluorophore, following the
expression in cells, are brought into close proximity as a result
of the specific protein interactions, which initiates folding of
the fragments into an active protein and results in a detectable
fluorescent signal at the site of the protein-protein complex.
Thus, through BiFC, the specific interaction between PB1 and PA
subunits can be visualized, quantified and localized within live
cells. By disrupting PB1-PA interaction with a compound of the
invention, the BiFC signal will be reduced, indicative of the
presence of potential inhibitors targeting the assembly of PB1-PA
complex. See Hemerka et. al., J. Virol. 2009, 3944-3955.
Pharmaceutical Compositions and Routes of Administration
[0262] The peptidomimetic macrocycles of the invention also include
pharmaceutically acceptable derivatives or prodrugs thereof. A
"pharmaceutically acceptable derivative" means any pharmaceutically
acceptable salt, ester, salt of an ester, pro-drug or other
derivative of a compound of this invention which, upon
administration to a recipient, is capable of providing (directly or
indirectly) a compound of this invention. Particularly favored
pharmaceutically acceptable derivatives are those that increase the
bioavailability of the compounds of the invention when administered
to a mammal (e.g., by increasing absorption into the blood of an
orally administered compound) or which increases delivery of the
active compound to a biological compartment (e.g., the brain or
lymphatic system) relative to the parent species. Some
pharmaceutically acceptable derivatives include a chemical group
which increases aqueous solubility or active transport across the
gastrointestinal mucosa.
[0263] In some embodiments, the peptidomimetic macrocycles of the
invention are modified by covalently or non-covalently joining
appropriate functional groups to enhance selective biological
properties. Such modifications include those which increase
biological penetration into a given biological compartment (e.g.,
blood, lymphatic system, central nervous system), increase oral
availability, increase solubility to allow administration by
injection, alter metabolism, and alter rate of excretion.
[0264] Pharmaceutically acceptable salts of the compounds of this
invention include those derived from pharmaceutically acceptable
inorganic and organic acids and bases. Examples of suitable acid
salts include acetate, adipate, benzoate, benzenesulfonate,
butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate,
glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride,
hydrobromide, hydroiodide, lactate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
palmoate, phosphate, picrate, pivalate, propionate, salicylate,
succinate, sulfate, tartrate, tosylate and undecanoate. Salts
derived from appropriate bases include alkali metal (e.g., sodium),
alkaline earth metal (e.g., magnesium), ammonium and
N-(alkyl).sub.4.sup.+ salts.
[0265] For preparing pharmaceutical compositions from the compounds
of the present invention, pharmaceutically acceptable carriers
include either solid or liquid carriers. Solid form preparations
include powders, tablets, pills, capsules, cachets, suppositories,
and dispersible granules. A solid carrier can be one or more
substances, which also acts as diluents, flavoring agents, binders,
preservatives, tablet disintegrating agents, or an encapsulating
material. Details on techniques for formulation and administration
are well described in the scientific and patent literature, see,
e.g., the latest edition of Remington's Pharmaceutical Sciences,
Maack Publishing Co, Easton Pa.
[0266] In powders, the carrier is a finely divided solid, which is
in a mixture with the finely divided active component. In tablets,
the active component is mixed with the carrier having the necessary
binding properties in suitable proportions and compacted in the
shape and size desired.
[0267] Suitable solid excipients are carbohydrate or protein
fillers include, but are not limited to sugars, including lactose,
sucrose, mannitol, or sorbitol; starch from corn, wheat, rice,
potato, or other plants; cellulose such as methyl cellulose,
hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose;
and gums including arabic and tragacanth; as well as proteins such
as gelatin and collagen. If desired, disintegrating or solubilizing
agents are added, such as the cross-linked polyvinyl pyrrolidone,
agar, alginic acid, or a salt thereof, such as sodium alginate.
[0268] Liquid form preparations include solutions, suspensions, and
emulsions, for example, water or water/propylene glycol solutions.
For parenteral injection, liquid preparations can be formulated in
solution in aqueous polyethylene glycol solution.
[0269] The pharmaceutical preparation is preferably in unit dosage
form. In such form the preparation is subdivided into unit doses
containing appropriate quantities of the active component. The unit
dosage form can be a packaged preparation, the package containing
discrete quantities of preparation, such as packeted tablets,
capsules, and powders in vials or ampoules. Also, the unit dosage
form can be a capsule, tablet, cachet, or lozenge itself; or it can
be the appropriate number of any of these in packaged form.
[0270] When the compositions of this invention comprise a
combination of a peptidomimetic macrocycle and one or more
additional therapeutic or prophylactic agents, both the compound
and the additional agent should be present at dosage levels of
between about 1 to 100%, and more preferably between about 5 to 95%
of the dosage normally administered in a monotherapy regimen. In
some embodiments, the additional agents are administered
separately, as part of a multiple dose regimen, from the compounds
of this invention. Alternatively, those agents are part of a single
dosage form, mixed together with the compounds of this invention in
a single composition.
Methods of Use
[0271] Generally, the invention discloses peptidomimetic
macrocycles useful in the treatment of viral disorders. For
example, peptidomimetic macrocycles derived from the PB1 helix
sequence, or peptidomimetic macrocycles that bind selectively to
the PB1 peptide binding site of the PA protein, may selectively
inhibit influenza RNA-dependent RNA polymerases. Peptidomimetic
macrocycles derived from the PB2 helix sequence, or peptidomimetic
macrocycles that bind selectively to the PB2 peptide binding site
of the PB1 protein, may selectively inhibit influenza RNA-dependent
RNA polymerases. When administered within a therapeutic window
after infection, such peptidomimetic macrocycles may reduce the
severity or duration of an influenza infection. When administered
prophylactically, such peptidomimetic macrocycles may prevent
infection by influenza viruses and thereby decrease the spread of
influenza and reduce large-scale epidemics.
[0272] In one aspect, the present invention provides novel
peptidomimetic macrocycles that are useful in competitive binding
assays to identify agents which bind to the natural ligand(s) of
the proteins or peptides upon which the peptidomimetic macrocycles
am modeled. For example, in the PB1/PA system, labeled
peptidomimetic macrocycles based on PB1 can be used in a PA binding
assay along with small molecules that competitively bind to PA.
Competitive binding studies allow for rapid in vitro evaluation and
determination of drug candidates specific for the PB1/PA system.
Such binding studies may be performed with any of the
peptidomimetic macrocycles disclosed herein and their binding
partners.
[0273] In other aspects, the present invention provides for both
prophylactic and therapeutic methods of treating a subject infected
with, at risk of, or susceptible to an influenza virus. These
methods comprise administering an effective amount of a compound of
the invention to a warm blooded animal, including a human. Tn some
embodiments, the administration of the compounds of the present
invention prevents the proliferation or transmission of an
influenza virus.
[0274] As used herein, the term "treatment" is defined as the
application or administration of a therapeutic agent to a patient,
or application or administration of a therapeutic agent to an
isolated tissue or cell line from a patient, who has a disease, a
symptom of disease or a predisposition toward a disease, with the
purpose to cure, heal, alleviate, relieve, alter, remedy,
ameliorate, improve or affect the disease, the symptoms of disease
or the predisposition toward disease.
[0275] In some embodiments, peptidomimetic macrocycles of the
invention are used to treat diseases induced by influenza viruses.
Like other viruses, the replication of influenza virus involves six
phases; transmission, entry, replication, biosynthesis, assembly,
and exit. Entry occurs by endocytosis, replication and vRNP
assembly takes place in the nucleus, and the virus buds from the
plasma membrane. In the infected patient, the virus targets airway
epithelial cells.
[0276] The methods described herein are also useful for development
and/or identification of agents for the treatment of infections
caused by viruses such as Abelson leukemia virus, Abelson murine
leukemia virus, Abelson's virus, Acute laryngotracheobronchitis
virus, Adelaide River virus, Adeno associated virus group,
Adenovirus, African horse sickness virus, African swine fever
virus, AIDS virus, Aleutian mink disease parvovirus,
Alpharetrovirus, Alphavirus, ALV related virus, Amapari virus,
Aphthovirus, Aquareovirus, Arbovirus, Arbovirus C, arbovirus group
A, arbovirus group B, Arenavirus group, Argentine hemorrhagic fever
virus, Argentine hemorrhagic fever virus, Arterivirus, Astrovirus,
Ateline herpesvirus group, Aujezky's disease virus, Aura virus,
Ausduk disease virus, Australian bat lyssavirus, Aviadenovirus,
avian erythroblastosis virus, avian infectious bronchitis virus,
avian leukemia virus, avian leukosis virus, avian lymphomatosis
virus, avian myeloblastosis virus, avian paramyxovirus, avian
pneumoencephalitis virus, avian reticuloendotheliosis virus, avian
sarcoma virus, avian type C retrovirus group, Avihepadnavirus,
Avipoxvirus, B virus, B19 virus, Babanki virus, baboon herpesvirus,
baculovirus, Barmah Forest virus, Bebaru virus, Berrimah virus,
Betaretrovirus, Birnavirus, Bittner virus, BK virus, Black Creek
Canal virus, bluetongue virus, Bolivian hemorrhagic fever virus,
Boma disease virus, border disease of sheep virus, boma virus,
bovine alphaherpesvirus 1, bovine alphaherpesvirus 2, bovine
coronavirus, bovine ephemeral fever virus, bovine immunodeficiency
virus, bovine leukemia virus, bovine leukosis virus, bovine
mammillitis virus, bovine papillomavirus, bovine papular stomatitis
virus, bovine parvovirus, bovine syncytial virus, bovine type C
oncovirus, bovine viral diarrhea virus, Buggy Creek virus, bullet
shaped virus group, Bunyamwera virus supergroup, Bunyavirus,
Burkitt's lymphoma virus, Bwamba Fever, CA virus, Calicivirus,
California encephalitis virus, camelpox virus, canarypox virus,
canid herpesvirus, canine coronavirus, canine distemper virus,
canine herpesvirus, canine minute virus, canine parvovirus, Cano
Delgadito virus, caprine arthritis virus, caprine encephalitis
virus, Caprine Herpes Virus, Capripox virus, Cardiovirus, cavlid
herpesvirus 1, Cereopithecid herpesvirus 1, cercopithecine
herpesvirus 1, Cercopithecine herpesvirus 2, Chandipura virus,
Changuinola virus, channel catfish virus, Charleville virus,
chickenpox virus, Chikungunya virus, chimpanzee herpesvirus, chub
reovirus, chum salmon virus, Cocal virus, Coho salmon reovirus,
coital exanthema virus, Colorado tick fever virus, Coltivirus,
Columbia SK virus, common cold virus, contagious ecthyma virus,
contagious pustular dermatitis virus, Coronavirus, Corriparta
virus, coryza virus, cowpox virus, coxsackie virus, CPV
(cytoplasmic polyhedrosis virus), cricket paralysis virus,
Crimean-Congo hemorrhagic fever virus, croup associated virus,
Cryptovirus, Cypovirus, Cytomegalovirus, cytomegalovirus group,
cytoplasmic polyhedrosis virus, deer papillomavirus,
deltaretrovirus, dengue virus, Densovirus, Dependovirus, Dhori
virus, diploma virus, Drosophila C virus, duck hepatitis B virus,
duck hepatitis virus 1, duck hepatitis virus 2, duovirus, Duvenhage
virus, Deformed wing virus DWV, eastern equine encephalitis virus,
eastern equine encephalomyelitis virus, ER virus, Ebola virus,
Ebola-like virus, echo virus, echovirus, echovirus 10, echovirus
28, echovirus 9, ectromelia virus, EEE virus, EIA virus, EIA virus,
encephalitis virus, encephalomyocarditis group virus,
encephalomyocarditis virus, Enterovirus, enzyme elevating virus,
enzyme elevating virus (LDH), epidemic hemorrhagic fever virus,
epizootic hemorrhagic disease virus, Epstein-Barr virus, equid
alphaherpesvirus 1, equid alphaherpesvirus 4, equid herpesvirus 2,
equine abortion virus, equine arteritis virus, equine encephalosis
virus, equine infectious anemia virus, equine morbillivirus, equine
rhinopneumonitis virus, equine rhinovirus, Euhenangu virus,
European elk papillomavirus, European swine fever virus, Everglades
virus, Eyach virus, felid herpesvirus 1, feline calicivirus, feline
fibrosarcoma virus, feline herpesvirus, feline immunodeficiency
virus, feline infectious peritonitis virus, feline leukemia/sarcoma
virus, feline leukemia virus, feline panleukopenia virus, feline
parvovirus, feline sarcoma virus, feline syncytial virus,
Filovirus, Flanders virus, Flavivirus, foot and mouth disease
virus, Fort Morgan virus, Four Corners hantavirus, fowl adenovirus
1, fowlpox virus, Friend virus, Gammaretrovirus, GB hepatitis
virus, GB virus, German measles virus, Getah virus, gibbon ape
leukemia virus, glandular fever virus, goatpox virus, golden
shinner virus, Gonometa virus, goose parvovirus, granulosis virus,
Gross' virus, ground squirrel hepatitis B virus, group A arbovirus,
Guanarito virus, guinea pig cytomegalovirus, guinea pig type C
virus, Hantaan virus, Hantavirus, hard clam reovirus, hare fibroma
virus, HCMV (human cytomegalovirus), hemadsorption virus 2,
hemagglutinating virus of Japan, hemorrhagic fever virus, hendra
virus, Henipaviruses, Hepadnavirus, hepatitis A virus, hepatitis B
virus group, hepatitis C virus, hepatitis D virus, hepatitis delta
virus, hepatitis E virus, hepatitis F virus, hepatitis G virus,
hepatitis nonA nonB virus, hepatitis virus, hepatitis virus
(nonhuman), hepatoencephalomyelitis reovirus 3, Hepatovirus, heron
hepatitis B virus, herpes B virus, herpes simplex virus, herpes
simplex virus 1, herpes simplex virus 2, herpesvirus, herpesvirus
7, Herpesvirus ateles, Herpesvirus hominis, Herpesvirus infection,
Herpesvirus saimiri, Herpesvirus suis, Herpesvirus varicellae,
Highlands J virus, Hirame rhabdovirus, hog cholera virus, human
adenovirus 2, human alphaherpesvirus 1, human alphaherpesvirus 2,
human alphaherpesvirus 3, human B lymphotropic virus, human
betaherpesvirus 5, human coronavirus, human cytomegalovirus group,
human foamy virus, human gammaherpesvirus 4, human gammaherpesvirus
6, human hepatitis A virus, human herpesvirus 1 group, human
herpesvirus 2 group, human herpesvirus 3 group, human herpesvirus 4
group, human herpesvirus 6, human herpesvirus 8, human
immunodeficiency virus, human immunodeficiency virus 1, human
immunodeficiency virus 2, human papillomavirus, human T cell
leukemia virus, human T cell leukemia virus I, human T cell
leukemia virus II, human T cell leukemia virus DI, human T cell
lymphoma virus I, human T cell lymphoma virus II, human T cell
lymphotropic virus type 1, human T cell lymphotropic virus type 2,
human T lymphotropic virus I, human T lymphotropic virus II, human
T lymphotropic virus III, Ichnovirus, infantile gastroenteritis
virus, infectious bovine rhinotracheitis virus, infectious
haematopoietic necrosis virus, infectious pancreatic necrosis
virus, influenza virus A, influenza virus B, influenza virus C,
influenza virus D, influenza virus pr8, insect iridescent virus,
insect virus, iridovirus, Japanese B virus, Japanese encephalitis
virus, JC virus, Junin virus, Kaposi's sarcoma-associated
herpesvirus, Kemerovo virus, Kilham's rat virus, Klamath virus,
Kolongo virus, Korean hemorrhagic fever virus, kumba virus, Kysanur
forest disease virus, Kyzylagach virus, La Crosse virus, lactic
dehydrogenase elevating virus, lactic dehydrogenase virus, Lagos
bat virus, Langur virus, lapine parvovirus, Lassa fever virus,
Lassa virus, latent rat virus, LCM virus, Leaky virus, Lentivirus,
Leporipoxvirus, leukemia virus, leukovirus, lumpy skin disease
virus, lymphadenopathy associated virus, Lymphocryptovirus,
lymphocytic choriomeningitis virus, lymphoproliferative virus
group, Machupo virus, mad itch virus, mammalian type B oncovirus
group, mammalian type B retroviruses, mammalian type C retrovirus
group, mammalian type D retroviruses, mammary tumor virus, Mapuera
virus, Marburg virus, Marburg-like virus, Mason Pfizer monkey
virus, Mastadenovirus, Mayaro virus, ME virus, measles virus,
Menangle virus, Mengo virus, Mengovirus, Middelburg virus, milkers
nodule virus, mink enteritis virus, minute virus of mice, MLV
related virus, MM virus, Mokola virus, Molluscipoxvirus, Molluscum
contagiosum virus, monkey B virus, monkeypox virus,
Mononegavirales, Morbillivirus, Mount Elgon bat virus, mouse
cytomegalovirus, mouse encephalomyelitis virus, mouse hepatitis
virus, mouse K virus, mouse leukemia virus, mouse mammary tumor
virus, mouse minute virus, mouse pneumonia virus, mouse
poliomyelitis virus, mouse polyomavirus, mouse sarcoma virus,
mousepox virus, Mozambique virus, Mucambo virus, mucosal disease
virus, mumps virus, murid betaherpesvirus 1, murid eytomegalovirus
2, murine cytomegalovirus group, murine encephalomyelitis virus,
murine hepatitis virus, murine leukemia virus, murine nodule
inducing virus, murine polyomavirus, murine sarcoma virus,
Muromegalovirus, Murray Valley encephalitis virus, myxoma virus,
Myxovirus, Myxovirus multiforme, Myxovirus parotitidis, Nairobi
sheep disease virus, Nairovirus, Nanimavirus, Nariva virus, Ndumo
virus, Neethling virus, Nelson Bay virus, neurotropic virus, New
World Arenavirus, newborn pneumonitis virus, Newcastle disease
virus, Nipah virus, noncytopathogenic virus, Norwalk virus, nuclear
polyhedrosis virus (NPV), nipple neck virus, O'nyong'nyong virus,
Ockelbo virus, oncogenic virus, oncogenic viruslike particle,
oncornavirus, Orbivirus, Orf virus, Oropouche virus,
Orthohepadnavirus, Orthomyxovirus, Orthopoxvirus, Orthoreovirus,
Orungo, ovine papillornavirus, ovine catarrhal fever virus, owl
monkey herpesvirus, Palyam virus, Papillomavirus, Papillomavirus
sylvilagi, Papovavirus, parainfluenza virus, parainfluenza virus
type 1, parainfluenza virus type 2, parainfluenza virus type 3,
parainfluenza virus type 4, Paramyxovirus, Parapoxvirus,
paravaccinia virus, Parvovirus, Parvovirus B19, parvovirus group,
Pestivirus, Phlebovirus, phocine distemper virus, Picodnavirus,
Picornavirus, pig cytomegalovirus-pigconpox virus, Piry virus,
Pixuna virus, pneumonia virus of mice, Pneumovirus, poliomyelitis
virus, poliovirus, Polydnavirus, polyhedral virus, polyoma virus,
Polyomavirus, Polyomavirus bovis, Polyomavirus cercopitheci,
Polyomavirus hominis 2, Polyomavirus maccacac 1, Polyomavirus muris
1, Polyomavirus muris 2, Polyomavirus papionis 1, Polyomavirus
papionis 2, Polyomavirus sylvilagi, Pongine herpesvirus 1, porcine
epidemic diarrhea virus, porcine hemagglutinating encephalomyelitis
virus, porcine parvovirus, porcine transmissible gastroenteritis
virus, porcine type C virus, pox virus, poxvirus, poxvirus
variolac, Prospect Hill virus, Provirus, pseudocowpox virus,
pseudorabies virus, psittacincpox virus, quailpox virus, rabbit
fibroma virus, rabbit kidney vaculolating virus, rabbit
papillomavirus, rabies virus, raccoon parvovirus, raccoonpox virus,
Ranikhet virus, rat cytomegalovirus, rat parvovirus, rat virus,
Rauscher's virus, recombinant vaccinia virus, recombinant virus,
reovirus, reovirus 1, reovirus 2, reovirus 3, reptilian type C
virus, respiratory infection virus, respiratory syncytial virus,
respiratory virus, reticuloendotheliosis virus, Rhabdovirus,
Rhabdovirus carpia, Rhadinovirus, Rhinovirus, Rhizidiovirus, Rift
Valley fever virus, Riley's virus, rinderpest virus, RNA tumor
virus, Ross River virus, Rotavirus, rougeole virus, Rous sarcoma
virus, rubella virus, rubeola virus, Rubivirus, Russian autumn
encephalitis virus, SA 11 simian virus, SA2 virus, Sabia virus,
Sagiyama virus, Saimirine herpesvirus 1, salivary gland virus,
sandfly fever virus group, Sandjimba virus, SARS virus, SDAV
(sialodacryoadenitis virus), sealpox virus, Semliki Forest Virus,
Seoul virus, sheeppox virus, Shope fibroma virus, Shope papilloma
virus, simian foamy virus, simian hepatitis A virus, simian human
immunodeficiency virus, simian immunodeficiency virus, simian
parainfluenza virus, simian T cell lymphotrophic virus, simian
virus, simian virus 40, Simplexvirus, Sin Nombre virus, Sindhis
virus, smallpox virus, South American hemorrhagic fever viruses,
sparrowpox virus, Spumavirus, squirrel fibroma virus, squirrel
monkey retrovirus, SSV 1 virus group, STLV (simian T lymphotropic
virus) type I, STLV (simian T lymphotropic virus) type II, STLV
(simian T lymphotropic virus) type III, stomatitis papulosa virus,
submaxillary virus, suid alphaherpesvirus 1, suid herpesvirus 2,
Suipoxvirus, swamp fever virus, swinepox virus, Swiss mouse
leukemia virus, TAC virus, Tacaribe complex virus, Tacarihe virus,
Tanapox virus, Taterapox virus, Tench reovirus, Theiler's
encephalomyelitis virus, Theiler's virus, Thogoto virus,
Thottapalayam virus, Tick borne encephalitis virus, Tioman virus,
Togavirus, Torovirus, tumor virus, Tupaia virus, turkey
rhinotracheitis virus, turkeypox virus, type C retroviruses, type D
oncovirus, type 17 retrovirus group, ulcerative disease
rhabdovirus, Una virus, Uukuniemi virus group, vaccinia virus,
vacuolating virus, varicella zoster virus, Varicellovirus, Varicola
virus, variola major virus, variola virus, Vasin Gishu disease
virus, VEE virus, Venezuelan equine encephalitis virus, Venezuelan
equine encephalomyelitis virus, Venezuelan hemorrhagic fever virus,
vesicular stomatitis virus, Vesiculovirus, Vilyuisk virus, viper
retrovirus, viral haemorrhagic septicemia virus, Visna Maedi virus,
Visna virus, volepox virus, VSV (vesicular stomatitis virus),
Wallal virus, Warrego virus, wart virus, WEE virus, West Nile
virus, western equine encephalitis virus, western equine
encephalomyelitis virus, Whataroa virus, Winter Vomiting Virus,
woodchuck hepatitis B virus, woolly monkey sarcoma virus, wound
tumor virus, WRSV virus, Yaba monkey tumor virus, Yaba virus,
Yatapoxvirus, yellow fever virus, and the Yug Bogdanovac virus. In
one embodiment an infectome will be produced for each virus that
includes an inventory of the host cellular genes involved in virus
infection during a specific phase of viral infection, such cellular
entry or the replication cycle.
[0277] For some viruses a great deal of progress has been made in
the elucidation of the steps involved during infection of host
cells, and any of these steps may be targeted using peptidomimetic
macrocycles of the invention. For example, experiments initiated in
the early 1980s showed that influenza virus follows a stepwise,
endocytic entry program with elements shared with other viruses
such as alpha- and rhabdoviruses (Marsh and Helenius 1989;
Whittaker 2006). The steps include: 1) Initial attachment to sialic
acid containing glycoconjugates receptors on the cell surface; 2)
signaling induced by the virus particle; 3) endocytosis by
clathrin-dependent and clathrin-independent cellular mechanism; 4)
acid-induced, hemaglutinin (HA)-mediated penetration from late
endosomes; 5) acid-activated, M2 and matrix protein (M1) dependent
uncoating of the capsid; and, 6) intra-cytosolic transport and
nuclear import of vRNPs. These steps depend on assistance from the
host cell in the form of sorting receptors, vesicle formation
machinery, kinase-mediated regulation, organelle acidification,
and, most likely, activities of the cytoskeleton.
[0278] Influenza attachment to the cells surface occurs via binding
of the HA1 subunit to cell surface glycoproteins and glycolipids
that carry oligosaccharide moieties with terminal sialic acid
residues (Skehel and Wiley 2000). The linkage by which the sialic
acid is connected to the next saccharide contributes to species
specificity. Avian strains including H5N1 prefer an a-(2,3)-link
and human strains a-(2,6)-link (Matrosovich 2006). In epithelial
cells, binding occurs preferentially to microvilli on the apical
surface, and endocytosis occurs at base of these extensions (Matlin
1982). Whether receptor binding induces signals that prepare the
cell for the invasion is not yet known, but it is likely because
activation of protein kinase C and synthesis of
phopshatidylinositol-3-phosphate (PI3P) are required for efficient
entry (Sieczkarski et al. 2003; Whittaker 2006).
[0279] Endocytic internalization occurs within a few minutes after
binding (Matlin 1982; Yoshimura and Ohnishi 1984). In tissue
culture cells influenza virus makes use of three different types of
cellular processes; 1) preexisting clathrin coated pits, 2)
virus-induced clathrin coated pits, and 3) endocytosis in vesicles
without visible coat (Matlin 1982; Sieczkarski and Whittaker 2002;
Rust et al. 2004). Video microscopy using fluorescent viruses
showed the virus particles undergoing actin-mediated rapid motion
in the cell periphery followed by minus end-directed,
microtubule-mediated transport to the perinuclear area of the cell.
Live cell imaging indicated that the virus particles first entered
a subpopulation of mobile, peripheral early endosomes that carry
them deeper into the cytoplasm before penetration takes place
(Lakadamyali et al. 2003; Rust et al. 2004). The endocytic process
is regulated by protein and lipid kinases, the proteasome, as well
as by Rabs and ubiquitin-dependent sorting factors (Khor et al.
2003; Whittaker 2006).
[0280] The membrane penetration step is mediated by low pH-mediated
activation of the trimeric, metastable HA, and the conversion of
this Type I viral fusion protein to a membrane fusion competent
conformation (Maeda et al. 1981; White et al. 1982). This occurs
about 16 min after internalization, and the pH threshold varies
between strains in the 5.0-5.6 range. The target membrane is the
limiting membrane of intermediate or late endosomes. The mechanism
of fusion has been extensively studied (Kielian and Rey 2006).
Further it was observed that fusion itself does not seem to require
any host cell components except a lipid bilayer membrane and a
functional acidification system (Maeda et al. 1981; White et al.
1982). The penetration step is inhibited by agents such as
lysosomotropic weak bases, carboxylic ionophores, and proton pump
inhibitors (Malin 1982; Whittaker 2006).
[0281] To allow nuclear import of the incoming vRNPs, the capsid
has to be disassembled. This step involves acidification of the
viral interior through the amantadine-sensitive M2-channels causes
dissociation of Mlfrom the vRNPs (Bukrinskaya ct al. 1982; Martin
and Helenius 1991; Pinto et al. 1992). Transport of the individual
vRNPs to the nuclear pore complexes and transfer into the nucleus
depends on cellular nuclear transport receptors (O'Neill ct al.
1995; Cros et al. 2005). Replication of the viral RNAs (synthesis
of positive and negative strands), and transcription occurs in
complexes tightly associated with the chromatin in the nucleus. It
is evident that, although many of the steps are catalyzed by the
viral polymerase, cellular factors are involved including RNA
polymerase activating factors, a chaperone HSP90, hCLF, and a human
splicing factor UAP56. Viral gene expression is subject to complex
cellular control at the transcriptional level, a control system
dependent on cellular kinases (Whittaker 2006).
[0282] The final assembly of an influenza particle occurs during a
budding process at the plasma membrane. In epithelial cells,
budding occurs at the apical membrane domain only (Rodriguez-Boulan
1983). First, the progeny vRNPs are transported within the
nucleoplasm to the nuclear envelope, then from the nucleus to the
cytoplasm, and finally they accumulate in the cell periphery. Exit
from the nucleus is dependent on viral protein NEP and M1, and a
variety of cellular proteins including CRM1 (a nuclear export
receptor), caspases, and possibly some nuclear protein chaperones.
Phosphorylation plays a role in nuclear export by regulating M1 and
NEP synthesis, and also through the MAPK/ERK system (Bui et al.
1996; Ludwig 2006). G protein and protein kinase signaling is
involved in influenza virus budding from infected host cells (Hui
E. and Nayak D, 2002).
[0283] The three membrane proteins of the virus are synthesized,
folded and assembled into oligomers in the ER (Doms et al. 1993).
They pass through the Golgi complex; undergo maturation through
modification of their carbohydrate moieties and proteolytic
cleavage. After reaching the plasma membrane they associate with M1
and the vRNPs in a budding process that results in the inclusion of
all eight vRNPs and exclusion of most host cell components except
lipids.
[0284] Influenza infection is associated with activation of several
signaling cascades including the MAPK pathway (ERK, JNK, p38 and
BMK-1/ERK5), the IkB/NF-kB signaling module, the Raf/MEK/ERK
cascade, and programmed cell death (Ludwig 2006). These result in a
variety of effects that limit the progress of infection such as
transcriptional activation of IFNb, apoptotic cell death, and a
block in virus escape of from late endosomes (Ludwig 2006).
Example 1
[0285] FIGS. 1 and 2 show a possible binding mode of the PB1
helix-derived sequence MDVNPTLLFLKVPAQ. A peptidomimetic macrocycle
of the invention is prepared starting with the corresponding
uncrosslinked polypeptide sequence MDVNPTLLFLKVPAQ and replacing
the 7.sup.th and 10.sup.th amino acids with an alpha,
alpha-disubstituted amino acid (e.g. the S5 olefin amino acid). An
olefin metathesis reaction is performed resulting in a
peptidomimetic macrocycle comprising an i to i+3 crosslink as shown
in FIG. 2b.
Example 2
[0286] Peptidomimetic macrocycles were synthesized, purified and
analyzed as previously described (Walensky et al (2004) Science
305:1466-70; Walensky et al (2006) Mol Cell 24:199-210; Bernal et
al (2007) J. Am Chem Soc. 9129, 2456-2457) and as indicated below.
The macrocycles used in this study are shown in Table 5. The
corresponding uncrosslinkod polypeptides represent the natural
counterparts of the peptidomimetic macrocycles of the
invention.
[0287] Alpha,alpha-disubstituted non-natural amino acids containing
olefinic side chains were synthesized according to Williams ct al.
(1991) J. Am. Chem. Soc. 113:9276; Schafmeister ct al. (2000) J.
Am. Chem Soc. 122:5891 and Verdine et al PCT WO 2008/121767.
Peptidomimetic macrocycles were designed by replacing two or more
naturally occurring amino acids with the corresponding synthetic
amino acids. Substitutions were made at the i and i+3, i and i+4, i
and i+6, and i and i+7 positions. Macrocycles were generated by
solid phase peptide synthesis followed by olefin metathesis-based
crosslinking of the synthetic amino acids via their
olefin-containing side chains.
[0288] In the sequences shown, the following abbreviations are
used: "Nle" represents norleucine, "Aib" represents
2-aminoisobutyric acid, "Ac" represents acetyl, and "Pr" represents
propionyl. Amino acids represented as "$" are alpha-Me
S5-pentenyl-alanine olefin amino acids connected by an all-carbon i
to i+4 crosslinker comprising one double bond. Amino acids
represented as "$r5" are alpha-Me R5-pentenyl-alanine olefin amino
acids connected by an all-carbon i to i+4 crosslinker comprising
one double bond. Amino acids represented as "$s8" are alpha-Me
88-octenyl-alanine olefin amino acids connected by an all-carbon i
to i+7 crosslinker comprising one double bond. Amino acids
represented as "$r8" are alpha-Me R8-octenyl-alanine olefin amino
acids connected by an all-carbon i to i+7 crosslinker comprising
one double bond. "Ahx" represents an aminocyclohexyl linker. The
crosslinkers are linear all-carbon crosslinker comprising eight or
eleven carbon atoms between the alpha carbons of each amino acid.
Amino acids represented as "$/" are alpha-Me R5-pentenyl-alanine
olefin amino acids that are not connected by any crosslinker. Amino
acids represented as "$/r5" are alpha-Me R5-pentenyl-alanine olefin
amino acids that are not connected by any crosslinker. Amino acids
represented as "$/s8" are alpha-Me S8-octenyl-alanine olefin amino
acids that are not connected by any crosslinker. Amino acids
represented as "$/r8" are alpha-Me R8-octenyl-alanine olefin amino
acids that are not connected by any crosslinker.
[0289] The non-natural amino acids (R and S enantiomers of the
5-carbon olefinic amino acid and the S enantiomer of the 8-carbon
olefinic amino acid) were characterized by nuclear magnetic
resonance (NMR) spectroscopy (Varian Mercury 400) and mass
spectrometry (Micromass LCT). Peptide synthesis was performed
either manually or on an automated peptide synthesizer (Applied
Biosystems, model 433A), using solid phase conditions, rink amide
AM resin (Novabiochem), and Fmoc main-chain protecting group
chemistry. For the coupling of natural Fmoc-protected amino acids
(Novabiochem), 10 equivalents of amino acid and a 1:1:2 molar ratio
of coupling reagents HBTU/HOBt (Novabiochem)/DIEA were employed.
Non-natural amino acids (4 equiv) were coupled with a 1:1:2 molar
ratio of HATU (Applied Biosystems)/HOBt/DIEA. Olefin metathesis was
performed in the solid phase using 10 mM Grubbs catalyst
(Blackewell et al. 1994 supra) (Strem Chemicals) dissolved in
degassed dichloromethane and reacted for 2 hours at room
temperature. Isolation of metathesized compounds was achieved by
trifluoroacetic acid-mediated deprotection and cleavage, ether
precipitation to yield the crude product, and high performance
liquid chromatography (HPLC) (Varian ProStar) on a reverse phase
C18 column (Varian) to yield the pure compounds. Chemical
composition of the pure products was confirmed by LC/MS mass
spectrometry (Micromass LCT interfaced with Agilent 1100 HPLC
system) and amino acid analysis (Applied Biosystems, model
420A).
[0290] The synthesized peptides include a norleucine replacement
for methionine to avoid issues with unwanted thioether oxidation.
In several peptides, the proline residue is replaced with a
2-aminoisobutyric acid residue (Aib) to increase helicity, and the
effect of Glu-to-Arg substitution on cell penetrability was also
explored. The N-termini of the synthetic peptides were acetylated,
while the C-termini were amidated. Table 5 shows a list of
peptidomimetic macrocycles of the invention prepared.
TABLE-US-00008 TABLE 5 PB1 Peptidomimetic macrocycles of the
invention. Found Macrocycle Sequence BMW M + 2H M + 2H SP-1
Ac-NleDVNPTLLFLKVPAQ-NH2 1707.99 854.995 854.86 SP-2
Ac-NleDVNAibTLLFLKVAibAQ-NH2 1683.99 842.995 843.35 SP-3
Ac-NleDVNPTLLFLKVPAR-NH2 1736.04 869.02 869.21 SP-4
Ac-TLLFLKVPAQ-NH2 1169.72 585.86 585.71 SP-5 Ac-TLLF$KVA$Q-NH2
1209.75 605.875 605.75 SP-6 Ac-NleDVNAibTLLF$KVA$R-NH2 1764.07
883.035 882.91 SP-7 Ac-NleDVNAibTL$FLK$AAR-NH2 1736.04 869.02
869.35 SP-8 Ac-NleDVNAibTLLF$KVA$Q-NH2 1736.02 869.01 868.82 SP-9
Ac-NleDVNAibTL$FLK$AAQ-NH2 1707.99 854.995 854.86 SP-10
Ac-NleDVNPTL$FLK$AAQ-NH2 1719.99 860.995 860.82 SP-11
Ac-NleDVNPTLLF$KVA$R-NH2 1776.07 889.035 888.87 SP-12
Ac-NleDVNPTL$FLK$AAR-NH2 1748.04 875.02 874.91 SP-13
Ac-NleDVNPT$r8LFLKV$AQ-NH2 1790.07 896.035 895.88 SP-14
Ac-NleDVNAibT$r8LFLKVA$Q-NH2 1778.07 890.035 890.22 SP-15
Ac-NlcDVNAibT$r8LFLKVA$R-NH2 1806.11 904.055 904.25 SP-16
Ac-NleDVNPT$r8LFLKVA$Q-NH2 1790.07 896.035 896.24 SP-17
Ac-NleDVNPT$r8LFLKVA$R-NH2 1818.11 910.055 910.26 SP-18
Ac-NleDVNATLLF$KVA$R-NH2 1750.05 876.025 876.19 SP-19
Ac-NleDVNATISFLKMAR-NH2 1722.02 862.01 862.23 SP-20
Ac-NlcDVNATLLF$KVA$Q-NH2 1722.01 862.005 862.23 SP-21
Ac-NleDVNATL$FLK$AAQ-NII2 1693.98 847.99 848.21 SP-22
Ac-TL$FLK$AAQ-NH2 1181.72 591.86 592.07 SP-23
FITC-AhxNleDVNAibTLLF$KVA$Q-NH2 2196.13 1099.065 1099.28 SP-24
5-FAM-AhxNleDVNAibILLFLKVAibAQ- 2113.11 1057.555 1057.85 NH2 SP-25
5-FAM-AhxNleDVNAibTL$FLK$AAQ-NH2 2137.11 1069.555 1069.82 SP-26
5-FAM-AhxNleDVNPTL$FLK$AAQ-NH2 2149.11 1075.555 1075.71 SP-27
5-FAM-AhxNleDVNAibT$r8LFLKVA$Q-NH2 2207.19 1104.595 1104.98 SP-28
5-FAM-AhxNleDVNPT$r8LFLKVA$Q-NII2 2219.19 1110.595 1110.81 SP-29
5-FAM-AhxNIeDVNAibT$r5LF$KVAibAR- 2165.16 1083.58 1083.94 NH2 SP-30
5-FAM-AhxNleDVNAibTLLF$/KVAVQ-NH2 2193.18 1097.59 1097.92 SP-31
Ac-NleDVNAibTLLFS/KVAS/R-NH2 1792.1 897.05 897.3 SP-32
Ac-NlcDVNPTLLFS/KVAS/R-NH2 1804.1 903.05 903.32 SP-33
Ac-NleDVNPTL$/FLK$/AAR-NII2 1776.07 889.035 889.27 SP-34
Ac-NleDVNAibTLVFLKS/AAR-NH2 1764.07 883.035 883.25 SP-35
Ac-NleDVNAibT$/r5LF$/KVAibAR-NH2 1764.07 883.035 883.31 SP-36
Ac-NleDVNAibTLL$/r5LKS/AAR-NH2 1730.08 866.04 866.29 SP-37
Ac-NleDVNAibT$/r8LFLKVAS/R-NH2 1834.15 918.075 918.34 SP-38
Ac-NleDVNPT$/r8LFLKVA$/R-NH2 1846.15 924.075 924.36 SP-39
Ac-NleDVNPT$/r8LFLKVA$/Q-NH2 1818.1 910.05 910.31 SP-40
Ac-NIeDVNAT$/r8LFLKVA$/Q-NH2 1792.09 897.045 897.3 SP-41
Ac-NleDVNAibTSr5LF$KVAibAR-NH2 1736.04 869.02 869.21 SP-42
Ac-NleDVNAibTLL$r5LK$AAR-NH2 1702.05 852.025 852.25 SP-43
Ac-NleDVNAT$r8LFLKVA$Q-NH2 1764.06 883.03 883.31 SP-44
5-FAM-AhxNleDVNAibTLLF$KVA$Q-NH2 2165.15 1083.575 1083.81 SP-45
Ac-NleDVNP$LLF$KVAibAR-NH2 1760.07 881.035 881.31 SP-46
Ac-NleDVNPTLL$LKV$AR-NH2 1742.08 872.04 872.31 SP-47
Ac-NleDVNAibTLL$LKV$AR-NH2 1730.08 866.04 866.29 SP-48
Ac-NleDVN$TLL$LKVAibAQ-NH2 1702.04 852.02 852.3 SP-49
Ac-NleDVNP$LLF$KVAibAQ-NII2 1732.03 867.015 867.26 SP-50
Ac-NleDVNPS/LLFS/KVAibAR-NH2 1788.1 895.05 895.29 SP-51
Ac-NleDVNPTLL$/LKV$/AR-NH2 1770.11 886.055 886.36 SP-52
Ac-NIeDVNAibTLL$/LKV$/AR-NH2 1758.11 880.055 880.34 SP-53
Ac-NlcDVN$/TLL$/LKVAibAQ-NH2 1730.07 866.035 866.29 SP-54
Ac-NleDVNPS/LLFS/KVAibAQ-NII2 1760.06 881.03 881.31 SP-55
Ac-NleDVNAibILLFLKVAAQ-NH2 1669.98 835.99 836.19 SP-56
5-FAM-AhxNleDVNAibTLLF$KVA$R-NH2 2193.19 1097.595 1098.31 SP-57
5-FAM-AhxNleDVNPTLLF$KVA$R-NH2 2205.19 1103.595 1104.27 SP-58
5-FAM-AhxNlcDVNPTL$FLICSAAR-NH2 2177.16 1089.58 1090.15 SP-59
5-FAM-AhxNleDVNAibTL$FLK$AAR-NII2 2165.16 1083.58 1084.26 SP-60
5-FAM-AhxNleDVNAibTLL$r5LK$AAR-NH2 2131.17 1066.585 1067.29 SP-61
5-FAM-AhxNleDVNAibT$r8LFLKVA$R-NH2 2235.23 1118.615 1119.29 SP-62
5-FAM-AhxNleDVNPT$r8LFLKVA$R-NH2 2247.23 1124.615 1125.31 SP-63
5-FAM-AhxNleDVNAT$r8LFLKVA$Q-NH2 2193.18 1097.59 1098.25 SP-64
5-FAM-AhxNleDVNAibTLLFLKVAAQ-NII2 2099.1 1050.55 1050.78
Example 3
[0291] The ex vivo serum stability of several PB1 peptidomimetic
macrocycles was tested by incubating them at 5000 ng/mL (2 .mu.M at
MW=2500) with fresh human serum at 37.degree. C. and taking samples
at 0, 0.5, 1, 2, 4, 6 and 24 hours. At each time point the samples
were flash-frozen until analysis in duplicate, then extracted by
transferring 100 .mu.l of sera to 2 ml centrifuge tubes followed by
the addition of 10 .mu.L of 50% formic acid and 500 .mu.L
acetonitrile and centrifugation at 14,000 RPM for 10 min at
4.+-.2.degree. C. After protein precipitation, the supernatants
were then transferred to fresh 2 ml tubes and evaporated on
Turbovap under N.sub.2 at <10 psi, 37.degree. C. The samples
were reconstituted in 100 .mu.L of 50:50 acetonitrile/water and
quantified by LC-MS/MS analysis. The response for each compound was
normalized to estimate a percent decrease in concentration versus
time; the results are shown in FIG. 3.
Example 4
[0292] Several PB1 peptidomimetic macrocycles were tested for PK
properties in single IV dose in rats. The in-life portion of the
study was conducted at ViviSource Laboratories (Waltham, Mass.). A
single intravenous dose of 3 mg/kg Stapled Peptide formulated in
water continuing 5% PEG-400 and 2% Dextrose was administered to a
pair of jugular vein-cannulated male Sprague-Dawley rats. The N
dose was mostly well-tolerated and animals appeared healthy within
the study duration. Blood samples were collected over thirteen
sampling times up to 24 hours and the plasma samples were shipped
on dry ice to Tandem Bioanalytical Facilities, Inc. (Woburn, Mass.)
for the analytical phase of the study.
[0293] Quantification in plasma samples was preceded by the
preparation of sample extracts by combining 50 .mu.l of ammonium
hydroxide (14.5 M ammonia), 1 mL of a 1:1 acetonitrile/methanol
solution, and 50 .mu.l of internal standard with 50 .mu.l of each
plasma sample. The mixtures were centrifuged to separate liquid
supernatant from solid precipitate and supernatants were dried at
40.degree. C. under flowing nitrogen gas. The dried sample extracts
were reconstituted in 50 .mu.l of a 1:1 water/methanol solution
that contained 0.1% (v/v) trifluoroacetic acid. Plasma sample
extracts were analyzed by a liquid chromatography-mass spectrometry
method that utilized an API 5000 (Applied Biosystems) instrument
operated in positive ionization mode at a temperature of
500.degree. C. using a multiple reaction monitoring mode of
detection (MRM). The analytical column for liquid chromatography
was a Varian Metasil C18, 50 mm.times.2 mm and mobile phases A
(0.1% formic acid in water) and B (0.1% formic acid in
acetonitrile) were pumped at a flow rate of 0.5 ml/min.
Quantification in plasma extracts was made by linear regression
analysis employing a pure reference standard Stapled Peptide
diluted in normal rat plasma to prepare eight calibration standards
over the working concentration range of 20-10,000 ng/ml. The
calibration standards were extracted in identical fashion as sample
extracts and analyzed before and after the sample extracts.
[0294] Pharmacokinetic parameters were calculated using a
non-compartmental model using the PK Functions add-in for Microsoft
Excel. The terminal elimination half-life was calculated as
ln(2)/(.lamda.z), where the rate constant (.lamda.z) was calculated
as -1 times the estimated slope of the log-concentration versus
time data over 2-12 hr. AUC values (hr*ng/ml) were calculated by
statistical moment and linear trapezoidal approximation methods
over time points of 0-24 hours and 24 hour concentration values
were divided by (.lamda.z) was added in order to extrapolate AUMC
and AUC values to infinite time. Total body clearance (per kg body
weight) was calculated as dose divided by AUC. The volume of
distribution at steady state (Vss) was calculated as the product of
clearance and mean residence time (MRT=AUC/AUMC). The PK results
are shown graphically in FIGS. 4, 5a-5f, and a table of determined
PK parameters is shown in FIG. 6.
[0295] An experiment was also performed to compare different modes
of administration. Subcutaneous injection of peptidomimetic
macrocycle was performed and compared to intravenous
administration. Two groups of two animals each were injected
subcutaneously with a 3 mg/kg dose. Plasma was collected at regular
time points (e.g. 5, 20 minutes; 1, 2, 4, 8 12, and 48 hours) and
the samples were analyzed as indicated above. The results are
plotted in FIG. 7.
[0296] While preferred embodiments of the present invention have
been shown and described herein, it will be obvious to those
skilled in the art that such embodiments are provided by way of
example only. Numerous variations, changes, and substitutions will
now occur to those skilled in the art without departing from the
invention. It should be understood that various alternatives to the
embodiments of the invention described herein may be employed in
practicing the invention. It is intended that the following claims
define the scope of the invention and that methods and structures
within the scope of these claims and their equivalents be covered
thereby.
Sequence CWU 1
1
129115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 1Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val
Pro Ala Gln 1 5 10 15 211PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 2Met Glu Arg Ile Lys Glu Leu
Arg Asn Leu Met 1 5 10 315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 3Met Asp Val Asn Pro Thr Leu
Leu Phe Leu Lys Val Pro Ala Gln 1 5 10 15 415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 4Met
Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val Pro Ala Gln 1 5 10 15
515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 5Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val
Pro Ala Gln 1 5 10 15 615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 6Xaa Asp Val Asn Xaa Xaa Leu
Xaa Phe Leu Lys Val Xaa Xaa Xaa 1 5 10 15 715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 7Xaa
Asp Val Asn Xaa Xaa Leu Leu Xaa Leu Lys Val Xaa Xaa Xaa 1 5 10 15
815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 8Xaa Asp Val Asn Xaa Xaa Xaa Leu Phe Xaa Lys Val
Xaa Xaa Xaa 1 5 10 15 915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 9Xaa Asp Val Asn Xaa Xaa Leu
Leu Xaa Leu Lys Xaa Xaa Xaa Xaa 1 5 10 15 1015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 10Xaa
Asp Val Asn Xaa Xaa Leu Leu Phe Xaa Lys Val Xaa Xaa Xaa 1 5 10 15
1115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 11Xaa Asp Val Asn Xaa Xaa Leu Leu Phe Leu Lys Xaa
Xaa Xaa Xaa 1 5 10 15 1211PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 12Xaa Xaa Leu Leu Phe Leu Lys
Val Xaa Xaa Xaa 1 5 10 1315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 13Met Asp Val Asn Xaa Thr Leu
Xaa Phe Leu Lys Val Pro Ala Gln 1 5 10 15 1415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 14Xaa
Asp Val Asn Xaa Xaa Leu Xaa Phe Leu Lys Val Xaa Xaa Gln 1 5 10 15
1515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 15Xaa Asp Val Asn Xaa Xaa Leu Xaa Phe Leu Lys Val
Xaa Xaa Arg 1 5 10 15 1615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 16Met Asp Val Asn Pro Xaa Leu
Leu Xaa Leu Lys Val Pro Ala Gln 1 5 10 15 1715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 17Xaa
Asp Val Asn Xaa Xaa Leu Leu Xaa Leu Lys Val Xaa Xaa Gln 1 5 10 15
1815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 18Xaa Asp Val Asn Xaa Xaa Leu Leu Xaa Leu Lys Val
Xaa Xaa Arg 1 5 10 15 1915PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 19Met Asp Val Asn Pro Thr Xaa
Leu Phe Xaa Lys Val Pro Ala Gln 1 5 10 15 2015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 20Xaa
Asp Val Asn Xaa Xaa Xaa Leu Phe Xaa Lys Val Xaa Xaa Gln 1 5 10 15
2115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 21Xaa Asp Val Asn Xaa Xaa Xaa Leu Phe Xaa Lys Val
Xaa Xaa Arg 1 5 10 15 2215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 22Met Asp Val Asn Pro Thr Leu
Leu Xaa Leu Lys Xaa Pro Ala Gln 1 5 10 15 2315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 23Xaa
Asp Val Asn Xaa Xaa Leu Leu Xaa Leu Lys Xaa Xaa Xaa Gln 1 5 10 15
2415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 24Xaa Asp Val Asn Xaa Xaa Leu Leu Xaa Leu Lys Xaa
Xaa Xaa Arg 1 5 10 15 2515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 25Met Asp Val Asn Pro Thr Leu
Leu Phe Xaa Lys Val Xaa Ala Gln 1 5 10 15 2615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 26Xaa
Asp Val Asn Xaa Xaa Leu Leu Phe Xaa Lys Val Xaa Xaa Gln 1 5 10 15
2715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 27Xaa Asp Val Asn Xaa Xaa Leu Leu Phe Xaa Lys Val
Xaa Xaa Arg 1 5 10 15 2815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 28Met Asp Val Asn Pro Thr Leu
Leu Phe Leu Lys Xaa Pro Ala Xaa 1 5 10 15 2915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 29Xaa
Asp Val Asn Xaa Xaa Leu Leu Phe Leu Lys Xaa Xaa Xaa Xaa 1 5 10 15
3010PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 30Thr Leu Leu Phe Leu Lys Val Pro Ala Gln 1 5 10
3110PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 31Xaa Leu Leu Phe Leu Lys Val Xaa Xaa Gln 1 5 10
3210PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 32Xaa Leu Leu Phe Leu Lys Val Xaa Xaa Arg 1 5 10
3311PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 33Xaa Glu Arg Ile Lys Glu Leu Arg Asn Leu Xaa 1 5
10 3411PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 34Xaa Glu Arg Ile Lys Glu Leu Arg Asn Leu Xaa 1 5
10 3511PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 35Xaa Glu Arg Ile Xaa Glu Leu Arg Asn Leu Xaa 1 5
10 3611PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 36Xaa Glu Arg Ile Xaa Glu Leu Arg Xaa Leu Xaa 1 5
10 3711PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 37Xaa Xaa Arg Ile Lys Xaa Leu Arg Asn Leu Xaa 1 5
10 3811PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 38Xaa Glu Arg Ile Lys Glu Leu Xaa Asn Leu Xaa 1 5
10 3911PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 39Xaa Xaa Arg Ile Lys Glu Leu Arg Xaa Leu Xaa 1 5
10 4012PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 40Xaa Xaa Glu Arg Ile Lys Glu Leu Arg Asn Leu Xaa
1 5 10 4112PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 41Xaa Xaa Glu Ala Ile Lys Glu Leu Arg Asn Leu Xaa
1 5 10 4212PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 42Xaa Xaa Glu Gly Ile Lys Glu Leu Arg Asn Leu Xaa
1 5 10 4311PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 43Xaa Glu Arg Ile Xaa Glu Leu Arg Asn Leu Met 1 5
10 4411PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 44Met Glu Arg Ile Xaa Glu Leu Arg Xaa Leu Met 1 5
10 4511PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 45Met Xaa Arg Ile Lys Xaa Leu Arg Asn Leu Met 1 5
10 4611PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 46Xaa Glu Arg Ile Lys Glu Leu Xaa Asn Leu Met 1 5
10 4711PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 47Met Xaa Arg Ile Lys Glu Leu Arg Xaa Leu Met 1 5
10 4811PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 48Met Glu Arg Ile Lys Glu Leu Arg Asn Leu Met 1 5
10 4911PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 49Met Glu Ala Ile Lys Glu Leu Arg Asn Leu Met 1 5
10 5011PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 50Met Glu Gly Ile Lys Glu Leu Arg Asn Leu Met 1 5
10 5111PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 51Xaa Glu Arg Ile Xaa Glu Leu Arg Asn Leu Xaa 1 5
10 5211PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 52Xaa Glu Arg Ile Xaa Glu Leu Arg Xaa Leu Xaa 1 5
10 5311PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 53Xaa Xaa Arg Ile Lys Xaa Leu Arg Asn Leu Xaa 1 5
10 5411PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 54Xaa Glu Arg Ile Lys Glu Leu Xaa Asn Leu Xaa 1 5
10 5511PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 55Xaa Xaa Arg Ile Lys Glu Leu Arg Xaa Leu Xaa 1 5
10 5611PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 56Xaa Glu Arg Ile Lys Glu Leu Arg Asn Leu Xaa 1 5
10 5711PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 57Xaa Glu Ala Ile Lys Glu Leu Arg Asn Leu Xaa 1 5
10 5811PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 58Xaa Glu Gly Ile Lys Glu Leu Arg Asn Leu Xaa 1 5
10 5915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 59Xaa Asp Val Asn Xaa Thr Leu Leu Phe Xaa Lys Val
Ala Xaa Gln 1 5 10 15 6015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 60Xaa Asp Val Asn Pro Thr Xaa
Leu Phe Leu Lys Val Ala Xaa Gln 1 5 10 15 6115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 61Xaa
Asp Val Asn Pro Thr Xaa Leu Phe Leu Lys Val Xaa Ala Gln 1 5 10 15
6215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 62Xaa Asp Val Asn Xaa Thr Xaa Leu Phe Xaa Leu Val
Xaa Ala Arg 1 5 10 15 6311PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 63Xaa Glu Arg Ile Xaa Glu Leu
Arg Asn Leu Met 1 5 10 6411PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 64Xaa Glu Arg Ile Lys Glu Leu
Xaa Asn Leu Met 1 5 10 6511PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 65Xaa Glu Ala Ile Lys Glu Leu
Arg Asn Leu Xaa 1 5 10 6615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 66Xaa Asp Val Asn Pro Thr Leu
Leu Phe Leu Lys Val Pro Ala Gln 1 5 10 15 6715PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 67Xaa
Asp Val Asn Xaa Thr Leu Leu Phe Leu Lys Val Xaa Ala Gln 1 5 10 15
6815PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 68Xaa Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val
Pro Ala Arg 1 5 10 15 6910PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 69Thr Leu Leu Phe Leu Lys Val
Pro Ala Gln 1 5 10 7010PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 70Thr Leu Leu Phe Xaa Lys Val
Ala Xaa Gln 1 5 10 7115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 71Xaa Asp Val Asn Xaa Thr Leu
Leu Phe Xaa Lys Val Ala Xaa Arg 1 5 10 15 7215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 72Xaa
Asp Val Asn Xaa Thr Leu Xaa Phe Leu Lys Xaa Ala Ala Arg 1 5 10
157315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 73Xaa Asp Val Asn Xaa Thr Leu Leu Phe Xaa Lys Val
Ala Xaa Gln 1 5 10 15 7415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 74Xaa Asp Val Asn Xaa Thr Leu
Xaa Phe Leu Lys Xaa Ala Ala Gln 1 5 10 157515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 75Xaa
Asp Val Asn Pro Thr Leu Xaa Phe Leu Lys Xaa Ala Ala Gln 1 5 10
157615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 76Xaa Asp Val Asn Pro Thr Leu Leu Phe Xaa Lys Val
Ala Xaa Arg 1 5 10 15 7715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 77Xaa Asp Val Asn Pro Thr Leu
Xaa Phe Leu Lys Xaa Ala Ala Arg 1 5 10 157815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 78Xaa
Asp Val Asn Pro Thr Xaa Leu Phe Leu Lys Val Xaa Ala Gln 1 5 10 15
7915PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 79Xaa Asp Val Asn Xaa Thr Xaa Leu Phe Leu Lys Val
Ala Xaa Gln 1 5 10 15 8015PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 80Xaa Asp Val Asn Xaa Thr Xaa
Leu Phe Leu Lys Val Ala Xaa Arg 1 5 10 15 8115PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 81Xaa
Asp Val Asn Pro Thr Xaa Leu Phe Leu Lys Val Ala Xaa Gln 1 5 10 15
8215PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 82Xaa Asp Val Asn Pro Thr Xaa Leu Phe Leu Lys Val
Ala Xaa Arg 1 5 10 15 8315PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 83Xaa Asp Val Asn Ala Thr Leu
Leu Phe Xaa Lys Val Ala Xaa Arg 1 5 10 15 8415PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 84Xaa
Asp Val Asn Ala Thr Leu Xaa Phe Leu Lys Xaa Ala Ala Arg 1 5 10
158515PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 85Xaa Asp Val Asn Ala Thr Leu Leu Phe Xaa Lys Val
Ala Xaa Gln 1 5 10 15 8615PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 86Xaa Asp Val Asn Ala Thr Leu
Xaa Phe Leu Lys Xaa Ala Ala Gln 1 5 10 158710PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 87Thr
Leu Xaa Phe Leu Lys Xaa Ala Ala Gln 1 5 108816PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 88Xaa
Xaa Asp Val Asn Xaa Thr Leu Leu Phe Xaa Lys Val Ala Xaa Gln 1 5 10
15 8916PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 89Xaa Xaa Asp Val Asn Xaa Thr Leu Leu Phe Leu Lys
Val Xaa Ala Gln 1 5 10 15 9016PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 90Xaa Xaa Asp Val Asn Xaa Thr
Leu Xaa Phe Leu Lys Xaa Ala Ala Gln 1 5 10 159116PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 91Xaa
Xaa Asp Val Asn Pro Thr Leu Xaa Phe Leu Lys Xaa Ala Ala
Gln 1 5 10 159216PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 92Xaa Xaa Asp Val Asn Xaa Thr Xaa Leu
Phe Leu Lys Val Ala Xaa Gln 1 5 10 15 9316PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 93Xaa
Xaa Asp Val Asn Pro Thr Xaa Leu Phe Leu Lys Val Ala Xaa Gln 1 5 10
15 9416PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 94Xaa Xaa Asp Val Asn Xaa Thr Xaa Leu Phe Xaa Lys
Val Xaa Ala Arg 1 5 10 15 9516PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 95Xaa Xaa Asp Val Asn Xaa Thr
Leu Leu Phe Xaa Lys Val Ala Xaa Gln 1 5 10 15 9615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 96Xaa
Asp Val Asn Xaa Thr Leu Leu Phe Xaa Lys Val Ala Xaa Arg 1 5 10 15
9715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 97Xaa Asp Val Asn Pro Thr Leu Leu Phe Xaa Lys Val
Ala Xaa Arg 1 5 10 15 9815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 98Xaa Asp Val Asn Pro Thr Leu
Xaa Phe Leu Lys Xaa Ala Ala Arg 1 5 10 159915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 99Xaa
Asp Val Asn Xaa Thr Leu Xaa Phe Leu Lys Xaa Ala Ala Arg 1 5 10
1510015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 100Xaa Asp Val Asn Xaa Thr Xaa Leu Phe Xaa Lys
Val Xaa Ala Arg 1 5 10 15 10115PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 101Xaa Asp Val Asn Xaa Thr
Leu Leu Xaa Leu Lys Xaa Ala Ala Arg 1 5 10 1510215PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 102Xaa
Asp Val Asn Xaa Thr Xaa Leu Phe Leu Lys Val Ala Xaa Arg 1 5 10 15
10315PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 103Xaa Asp Val Asn Pro Thr Xaa Leu Phe Leu Lys
Val Ala Xaa Arg 1 5 10 15 10415PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 104Xaa Asp Val Asn Pro Thr
Xaa Leu Phe Leu Lys Val Ala Xaa Gln 1 5 10 15 10515PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 105Xaa
Asp Val Asn Ala Thr Xaa Leu Phe Leu Lys Val Ala Xaa Gln 1 5 10 15
10615PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 106Xaa Asp Val Asn Xaa Thr Xaa Leu Phe Xaa Lys
Val Xaa Ala Arg 1 5 10 15 10715PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 107Xaa Asp Val Asn Xaa Thr
Leu Leu Xaa Leu Lys Xaa Ala Ala Arg 1 5 10 1510815PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 108Xaa
Asp Val Asn Ala Thr Xaa Leu Phe Leu Lys Val Ala Xaa Gln 1 5 10 15
10916PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 109Xaa Xaa Asp Val Asn Xaa Thr Leu Leu Phe Xaa
Lys Val Ala Xaa Gln 1 5 10 15 11015PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 110Xaa
Asp Val Asn Pro Xaa Leu Leu Phe Xaa Lys Val Xaa Ala Arg 1 5 10 15
11115PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 111Xaa Asp Val Asn Pro Thr Leu Leu Xaa Leu Lys
Val Xaa Ala Arg 1 5 10 15 11215PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 112Xaa Asp Val Asn Xaa Thr
Leu Leu Xaa Leu Lys Val Xaa Ala Arg 1 5 10 15 11315PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 113Xaa
Asp Val Asn Xaa Thr Leu Leu Xaa Leu Lys Val Xaa Ala Gln 1 5 10 15
11415PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 114Xaa Asp Val Asn Pro Xaa Leu Leu Phe Xaa Lys
Val Xaa Ala Gln 1 5 10 15 11515PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 115Xaa Asp Val Asn Pro Xaa
Leu Leu Phe Xaa Lys Val Xaa Ala Arg 1 5 10 15 11615PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 116Xaa
Asp Val Asn Pro Thr Leu Leu Xaa Leu Lys Val Xaa Ala Arg 1 5 10 15
11715PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 117Xaa Asp Val Asn Xaa Thr Leu Leu Xaa Leu Lys
Val Xaa Ala Arg 1 5 10 15 11815PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 118Xaa Asp Val Asn Xaa Thr
Leu Leu Xaa Leu Lys Val Xaa Ala Gln 1 5 10 15 11915PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 119Xaa
Asp Val Asn Pro Xaa Leu Leu Phe Xaa Lys Val Xaa Ala Gln 1 5 10 15
12015PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 120Xaa Asp Val Asn Xaa Thr Leu Leu Phe Leu Lys
Val Ala Ala Gln 1 5 10 15 12116PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 121Xaa Xaa Asp Val Asn Xaa
Thr Leu Leu Phe Xaa Lys Val Ala Xaa Arg 1 5 10 15
12216PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 122Xaa Xaa Asp Val Asn Pro Thr Leu Leu Phe Xaa
Lys Val Ala Xaa Arg 1 5 10 15 12316PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 123Xaa
Xaa Asp Val Asn Pro Thr Leu Xaa Phe Leu Lys Xaa Ala Ala Arg 1 5 10
1512416PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 124Xaa Xaa Asp Val Asn Xaa Thr Leu Xaa Phe Leu
Lys Xaa Ala Ala Arg 1 5 10 15 12516PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 125Xaa
Xaa Asp Val Asn Xaa Thr Leu Leu Xaa Leu Lys Xaa Ala Ala Arg 1 5 10
1512616PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 126Xaa Xaa Asp Val Asn Xaa Thr Xaa Leu Phe Leu
Lys Val Ala Xaa Arg 1 5 10 15 12716PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 127Xaa
Xaa Asp Val Asn Pro Thr Xaa Leu Phe Leu Lys Val Ala Xaa Arg 1 5 10
15 12816PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 128Xaa Xaa Asp Val Asn Ala Thr Xaa Leu Phe Leu
Lys Val Ala Xaa Gln 1 5 10 15 12916PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 129Xaa
Xaa Asp Val Asn Xaa Thr Leu Leu Phe Leu Lys Val Ala Ala Gln 1 5 10
15
* * * * *
References